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Zusammenfassung 
Bei der Behandlung maligner hämatologischer Erkrankungen wurden in den letzten 
Jahren große Fortschritte erzielt. Trotzdem kann die Mehrzahl der Patienten bisher 
nicht geheilt werden. Dies verlangt nach neuen Therapiestrategien, wie z.B. der 
Immuntherapie, deren Hauptziel es ist, eine zytotoxische Immunantworten gegen 
Tumor-assoziierte Antigene zu induzieren. 
Dendritische Zellen (DC) bieten aufgrund ihrer einzigartigen Fähigkeit zur 
Stimulation humoraler und zellulärer Immunantworten die besten Voraussetzungen 
über aktive Vakzinierung eine effiziente Anti-Tumor Immunantwort zu induzieren. 
Die Herstellung einer erfolgreichen anti-Tumor-Vakzine verlangt einerseits eine 
genaue Kenntnis der Physiologie der DC, andererseits müssen geeignete 
Vakzinierungsantigene charakterisiert werden. Die vorliegende Arbeit beschäftigt sich 
mit beiden Aspekten der Vakzineherstellung. 
Im ersten Teil der Arbeit werden MHC-Klasse-I Antigene (Peptide) aus den 
polymorphen Bereichen der HLA-DP-Allele sowie der konstanten Immunglobulin (A 
und D)-Regionen identifiziert und als mögliche Antigene zur Vakzinierung von 
Patienten mit hämatologischen Erkrankungen nach Stammzell-Transplantationen 
evaluiert. Dabei waren gegen eines der IgD-Peptide und gegen 11 der HLA-DP-
Peptide zytotoxische T-Zellen (CTL) induzierbar. CTL-Klone konnten jedoch nur 
gegen das IgD-Peptid gewonnen werden. Mit deren Hilfe gelang der Nachweis, dass 
dieses Peptid nicht auf der Oberfläche von normalen und malignen B-Zellen 
exprimiert wird und sich somit nicht als Vakzinierungsantigen eignet. Hingegen 
konnte die natürliche Präsentation der HLA-DP-Antigene wegen der 
Nichtklonierbarkeit der CTL nicht untersucht werden. Aufgrund der Immunogenität 
der Peptide sollte ihre Relevanz im Kontext einer allogenen Stammzell-
Transplantation weiter untersucht werden. 
Im zweiten Teil der Arbeit wird die Rolle der Glykogen-Synthase-Kinase (GSK)-3 bei 
der Differenzierung und Aktivierung humaner DC untersucht. Dabei kann gezeigt 
werden, dass 1) GSK-3 für die Differenzierung von DC aus Monozyten notwendig ist, 
2) GSK-3 konstitutiv in unreifen DC aktiv ist und deren spontane Reifung hemmt, 
und 3) GSK-3 im Kontext einer DC-Aktivierung eine neue, aktivierende Funktion 
aufgrund des sich ändernden intrazellulären Kontextes bekommt und die Sekretion 
großer Mengen inflammatorischer Zytokine (wie IL-12p70) vermittelt bzw. das anti-
inflammatorische IL-10 hemmt. 
Die Modulation der GSK-3-Aktivität im Rahmen einer Immuntherapie kann daher die 
Aktivierung Antigen-präsentierender DC verstärken und somit die Effizienz einer 
Vakzine verbessern. 
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Summary 
The treatment of haematological malignancies has achieved a significant progress 
during the last years; however, many subtypes of these diseases still remain incurable. 
Therefore, new complementary therapeutic approaches have to be developed. One 
possibility to enhance the effects of conventional chemo- and radiotherapy is provided 
by immunotherapy. The major aim of immunotherapy is to induce immune responses 
against antigens expressed by tumor cells, resulting in a therapeutic anti-tumor effect. 
Due to their unique capacity to stimulate both humoral and cell-mediated immune 
responses, dendritic cells (DC) are attractive candidates for active vaccination 
strategies. Intensive research is focused on improving the effectiveness of DC-based 
vaccines. The generation of successful anti-tumor vaccines requires both, a better 
understanding of the fundamental biology of DC, as well as the identification and 
characterization of tumor-associated antigens that can be used for vaccinations. The 
thesis presented here deals with both aspects of vaccine generation. 
In the first part of this thesis, MHC class I antigens derived from HLA-DP 
polymorphic regions and from immunoglobulin A and D constant regions were 
evaluated as potential targets for vaccination of patients with haematological 
malignancies after stem cell transplantation (SCT). CD8+ cytotoxic T-cell (CTL) 
responses could be generated in vitro against 1 IgD-derived peptide and 11 HLA-DP-
derived synthetic peptides. The IgD-derived epitope was demonstrated to lack 
efficient natural presentation on the surface of either normal or malignant cells and is 
therefore not a suitable target for vaccination. The characterization of natural 
presentation of the HLA-DP-derived peptides was not possible as peptide-specific 
CTL clones could not be generated. However, as immunogenicity of HLA-DP-
derived peptides was shown, further studies are proposed to investigate whether CTL 
recognizing these antigens have any impact on development of graft versus host 
disease in patients after HLA-DP mismatched allogeneic SCT. 
The second part of this thesis is focused on fundamental biology of DC. The role of 
the glycogen synthase kinase-3 (GSK-3) pathway in the differentiation of DC and 
regulation of DC functions was investigated using an in vitro model of human 
monocyte-derived DC. The results presented in this work demonstrate that (1) GSK-3 
is necessary for differentiation of monocytes into DC as in the absence of GSK-3 
activity monocytes differentiate into macrophage-like cells; (2) GSK-3 is 
constitutively active in immature DC and suppresses spontaneous maturation; (3) in 
the context of DC activation, GSK-3 acquires a pro-inflammatory function mediating 
high levels of IL-12p70, IL-6 and TNF-α secretion, and partially inhibits IL-10. 
Therefore, GSK-3 might become a target for therapeutic interventions in clinical 
immune imbalances, such as autoimmune diseases and transplantation settings. 
Modulation of this pathway during the course of vaccine-based immunotherapy may 
enhance DC activation in vivo and thus may enhance vaccine-mediated immune 
responses. 
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1 INTRODUCTION  
1.1  Immunotherapy against cancer 
Despite the introduction of new cytotoxic drugs, a large proportion of malignant 
diseases remains incurable. There is still a great need to develop new complementary 
therapeutic modalities. One possibility to enhance the effects of conventional chemo- 
and radiotherapy is provided by immunotherapy. Anti-tumor immunotherapy can be 
divided into two major approaches: non-specific and antigen-specific immunotherapy 
(reviewed in [1]) Non-specific immunotherapy includes immunostimulating cytokines 
and adoptive transfer of non-specific immune effector cells. Antigen-specific 
immunotherapy can be classified into passive (monoclonal antibodies, adoptive 
transfer of specific immune effector cells) and active vaccination strategies. This work 
is focused mainly on the active vaccination strategies. 
Vaccination against viral and bacterial pathogens represents a preventive treatment 
and is widely and successfully used in clinics. In contrast, vaccination against cancer 
aims at achieving therapeutic effect. In cancer patients, the immune system failed to 
recognize and fight the tumor cells. In this case, a successful vaccine should reverse 
the established tolerance to tumor antigens and overcome the tumor escape 
mechanisms. Therapeutic vaccination against an established malignancy still 
represents a great challenge for immunologists. 
1.1.1 Classification of tumor associated antigens 
Tumors express several antigens that allow the immune system to recognize the tumor 
as foreign. These antigens are called tumor-associated antigens (TAA). TAA can be 
recognized by T-cells as well as induce an antibody response. In order to direct the 
immune response against the tumor, TAA suitable for vaccinations have to be 
identified and characterized. Recent strategies of identifying TAA-derived T-cell 
epitopes’ include: 
1) Screening of tumor-derived cDNA libraries 
2) Comparison of gene expression profiles between tumors and normal tissues 
using microarray technology 
3) Theoretical epitope prediction on the basis of known HLA binding motifs 
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4) Elution and fractionation of  peptides naturally presented on the MHC of 
tumor cells  
TAA can be divided into several main groups according to their mutation- and 
expression patterns (reviewed in [2]): 
1) The expression of cancer-testis antigens in normal tissues is restricted mainly 
to spermatocytes/spermatogonia of testis, but they are expressed in many 
histologically different tumor types. This group of antigens includes the 
MAGE, BAGE and GAGE family of antigens, NY-ESO and the recently 
identified LAGE, SAGE, HAGE and several other antigens. 
2) Differentiation antigens are shared between the tumor and its normal parental 
tissue. The best studied differentiation antigens are melanoma-associated 
antigens, for instance Melan-A/MART1. 
3) Overexpressed antigens are antigens found in normal tissues, but they are 
amplified or overexpressed in tumors. This is the largest group of antigens that 
includes anti-apoptotic proteins (e.g. survivin and livin) and tumor-supressor 
proteins (e.g. p53). 
4) Unique TAA arise from point mutations, splicing aberrations as well as 
chromosome aberrations. The examples of unique TAA are the epitopes 
derived from mutated β-catenin, N-RAS and K-RAS. 
5) Viral antigens are the antigens encoded by oncogenic viruses, e.g. Epstein-
Barr virus (EBV) and human papilloma virus (HPV). 
1.2 Dendritic cells (DC) as potential adjuvants for anti-cancer 
immunotherapy 
DC are the most potent type of antigen presenting cells (APC) that play an important 
role in the induction of immune responses. Three main developmental stages can be 
distinguished – DC precursor, immature DC and mature DC. Immature DC (iDC) are 
distributed in tissues throughout the body and function as sentinels in the periphery. 
They sample the environment for presence of “danger signals” by multiple antigen 
uptake mechanisms. As soon as iDC detect a danger signal, they undergo a complex 
maturation process involving phenotypic and functional changes. In the process of 
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maturation, DC change their expression profile of surface markers resulting in an 
augmented capacity to activate naive and memory T-cell responses. They can also 
directly interact with other immune cell types, including natural killer (NK) cells, 
natural killer T-cells (NKT) and B-lymphocytes. Furthermore, DC may also secrete 
high levels of pro-inflammatory cytokines and acquire the capacity to migrate towards 
lymph nodes. These characteristics provide DC with a unique capacity of linking 
innate and adaptive immune responses. 
1.2.1 Dendritic cell differentiation and subtypes 
Dendritic cells originate from the hematopoietic precursors within the bone marrow. 
Two models have been proposed for the differentiation of DC from hematopoietic 
progenitor cells, one postulating that dendritic cells can be generated from either 
myeloid or lymphoid derived progenitors, the other postulating a single committed 
DC lineage that has functional plasticity (reviewed in [3]). Indeed, evidence generated 
by different experimental approaches in both mouse and human DC supports the 
notion that certain subsets of DC are of myeloid origin whereas others can be 
generated from lymphoid progenitors [3]. However, the concept of lymphoid versus 
myeloid DC progenitors was challenged by mouse experiments, showing that both 
myeloid and lymphoid DC (CD8- and CD8+, respectively) could be generated from 
common lymphoid [4] as well as common myeloid progenitors [5, 6]. Moreover, del 
Hoyo and coworkers could identify a CD11c+ MHC class II-, DC-committed 
precursor population which was capable of generating different DC subpopulations 
including CD8- and CD8+ DC [7]. This suggested the existence of a single committed 
DC lineage that has functional plasticity. Although mouse and human DC were shown 
to be generated from multiple precursor cells in vitro, it is unclear whether the 
generation of DC under different specific experimental conditions is relevant for in 
vivo situation. So far, it remains unknown how DC are generated in vivo. 
The population of DC is heterogeneous. In mice, three main subsets have been 
defined according to the surface markers and functional properties: CD8-CD205–
CD11b+CD4+/– myeloid DC, CD8+CD205+CD11b–CD4– lymphoid DC and CD11b–
B220+GR1+/– plasmacytoid DC [8]. 
In humans, DC subtypes are less well characterized due to the limiting availability of 
DC derived from various tissues. The information about human DC subtypes derives 
1. Introduction 
 4
mainly from in vitro studies. DC and DC precursors from human blood are divided 
into two main populations: conventional CD11c+CD123lo myeloid DC and CD11c-
CD123hi plasmacytoid DC [9]. Plasmacytoid DC are the major type I interferon 
(IFNα/β) producers and play an important role in innate anti-viral immunity [9]. 
Myeloid DC are commonly differentiated in vitro from CD14+ monocytes. Upon 
activation with different stimuli they can secrete pro-inflammatory cytokines IL-6, 
TNF and IL-12 and efficiently initiate adaptive immune responses [9]. 
Conventional human monocyte-derived myeloid DC are the main focus of this 
discussion. 
1.2.2 Mechanisms of Antigen Processing and Presentation 
Antigen presenting cells employ two major systems to present antigens to T-
lymphocytes - MHC class I and II. MHC class I is recognized by CD8+ cytotoxic T-
lymphocytes and MHC class II is recognized by CD4+ T-helper cells. 
1.2.2.1 MHC class II presentation 
MHC class II complex formation takes place in the endocytic pathway. The endocytic 
pathway is generally divided in 3 regions – early endosomes, late endosomes and 
lysosomes. Self or foreign endocytosed material moves predominantly from early 
endosomes towards lysosomes being exposed to increasingly acidic and proteolytic 
environment resulting in gradual release of polypeptides. Some of these peptides will 
occasionally have a proper sequence to bind MHC class II alleles. 
The MHC class II molecule is a heterodimer consisting of polymorphic α and β-
chains that form a peptide-binding groove open from both ends [10]. This allows for a 
certain variability in the length of the peptides that can bind to MHC class II. Most of 
the peptides contain 12-19 residues, although MHC class II binding peptides with a 
length up to 30 amino acids were identified, as reviewed in [11]. 
Newly synthesized MHC II molecules are cotranslationally translocated into the 
endoplasmic reticulum (ER) and assembled there with the chaperone invariant chain 
(Ii) (reviewed in [12]). Binding of MHC class II to Ii stabilizes the complex and 
prevents ER-resident polypeptides from binding to the peptide-binding grove of MHC 
class II [13]. Ii also contains the sorting signal for endosomal compartments [14, 15]. 
When the MHC class II-Ii complex reaches the endosomal compartment, Ii is 
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degraded stepwise by proteases, producing Ii-p22 and Ii-p10 intermediates and finally 
the CLIP fragment that occupies the peptide-binding cleft. This last step is performed 
by cathepsin S [16, 17]. The conversion of Ii-p10 into CLIP releases the MHC-II 
complex from the cytoplasmic part of Ii that contains the endosomal targeting motif. 
This motif acts as a retention signal that prevents MHC-II from escaping to the cell 
surface [18, 19]. Thus, after MHC class II is released from the Ii retention signal, the 
replacement of CLIP by the antigenic peptide has to occur rapidly in order to prevent 
surface expression of CLIP-loaded MHC molecules. The CLIP peptide is substituted 
by antigenic peptides with the help of the chaperones H-2DM and H-2DO (in humans, 
HLA-DM and HLA-DO) that destabilize the complex and facilitate the release of 
CLIP [20]. H-2DM has also been shown to execute a peptide editing function, 
promoting the exchange of low affinity for high affinity peptides [21]. 
1.2.2.2 MHC class I presentation 
Antigens derived from endogenous proteins are predominantly presented to CD8+ 
lymphocytes via the MHC class I presentation pathway. Endogenous proteins, 
including defective ribosome products (DRiPs) [22], are ubiquitinylated and thus 
targeted for degradation by proteasomes [23]. Proteasomes cleave these proteins to 
peptides of 3-22 residues [24]. These peptides can then be further processed by 
cytosolic peptidases, transported into the ER by the transporter associated with 
antigen presentation (TAP) and loaded on MHC-I molecules. MHC class I loading is 
a complex process which requires a macromolecular peptide loading complex 
comprised of MHC heavy chain, β2-microglobulin, TAP and chaperones, such as 
tapasin, calreticulin and ERp57 [25-27]. After peptide binding, MHC-class I is 
released from the peptide loading complex and transported via Golgi to the cell 
surface. 
Although mammalian cells express thousands of different proteins, which can give 
rise to numerous antigenic peptide variants, only a minor part of these antigens is 
naturally presented on MHC class I molecules. There are several mechanisms that 
contribute to the restriction of the antigen repertoire, including: 
1) Proteasomal cleavage specificity  
2) Sequence- and size preferences for peptide transfer into the ER by TAP 
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3) Allele-specific binding affinity of antigens to MHC-class I 
Proteasomes are believed to represent the main protease activity for the generation of 
MHC-class I peptides (reviewed in [28]). They contain few catalytic subunits with 
three distinct catalytic activities: chymotrypsin-like, trypsin-like and caspase-like 
(cleavage after hydrophobic residues, basic residues and acidic residues, respectively). 
Moreover, expression of several subunits of the proteasomal system 
(immunosubunits) [29] as well as proteasomal regulator PA28 [30] are controlled by 
IFN-γ. IFN-γ is produced by activated T-cells and NK-cells and was shown to 
enhance MHC-class I antigen presentation. Immunosubunits replace their constitutive 
counterparts within the active site, resulting in the formation of immunoproteasomes 
[31, 32]. Immunoproteasomes have altered cleavage site preferences and differ in 
cleavage rate [33, 34], resulting in the generation of different peptide pool for MHC-
class I presentation [35-37]. 
The peptides generated by proteasomal degradation are transported into the ER in an 
ATP-dependent manner by TAP [38, 39]. TAP is composed of two homologous 
subunits: TAP1 and TAP2. Apart from the preference for 8-16-mer peptides [40], 
TAP was demonstrated to have a certain selectivity for sequence of transported 
peptides. The first 3 N-terminal and the C-terminal residues of the peptide are 
important for binding to TAP. Specifically, the human TAP complex is selective for 
hydrophobic or charged residues at the C-terminus and in the second position; 
moreover, strongly hydrophobic residues in P3 and P7 increase the binding affinity of 
the peptides to TAP, whereas proline in the first three positions, as well as acidic 
residues in P1, P3 and P7 or an aromatic amino acid in P1, have strong deleterious 
effects [41]. TAP-deficient cells have a significantly diminished MHC-class I surface 
expression [42]. Because in the absence of functional TAP, the majority of TAP-
dependent MHC-class I antigens are not presented at cell surface, tumor cells lacking 
TAP function generally escape recognition and elimination by CD8+ T-cells [43-45]. 
However, a TAP-independent MHC-class I presentation pathway has been reported 
[46]. The peptides derived from C-terminus of the transmembrane- and soluble 
proteins of the secretory pathway have access to MHC class I molecules in ER in the 
absence of TAP activity [46]. It was recently shown by van Hall and colleagues, that 
some of these peptides, although derived from self antigens, are specifically presented 
by TAP-deficient tumor cells but not by normal cells. Thus, these peptides could serve 
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as neoantigens inducing cytotoxic T-lymphocyte (CTL) responses against TAP-
deficient tumor variants [47]. 
MHC class I molecules are composed of a membrane anchored heavy chain and the 
non-covalently bound small soluble protein β2-microglobulin. The heavy chain can be 
subdivided into 3 domains (α1-α3). Two distal domains α1 and α2 form a peptide-
binding groove that can bind short antigenic peptides (8-11 amino acids). Human 
MHC-class I genes are organized in the class I region of chromosome 6, which 
contains 3 loci: HLA-A, -B and -C. Each locus encodes the heavy chain of MHC class 
I. These genes are highly polymorphic. The amino acid variability is clustered within 
three main regions of α1 and α2, which are involved in the formation of the peptide-
binding groove. MHC class I molecules bind N- and C- terminal residues (anchor 
positions) of antigenic peptides which flank a variable sequence that is recognized by 
the T-cell receptor (TCR). Depending on the polymorphic amino acids in the peptide-
binding site, different class I alleles will bind different peptide motifs [11, 48]. For 
example, human HLA-A2.1 selects for Met, Leu or Ile in position P2 of the antigenic 
peptide and Val, Leu, Ile or Ala in position P9 [48, 49]. P1, P3 and P7 residues also 
contribute to the stability of the peptide-MHC interaction [50, 51]. Identification of 
allele-specific peptide binding motifs allowed the design of peptides that bind to 
MHC with high affinity and helped to predict MHC-binding epitopes within a known 
protein sequence. Increasing the peptide binding affinity to MHC molecule by 
substituting anchoring amino acids represents one of the strategies to improve the 
immune reaction against tumor antigens [52, 53].  
1.2.2.3 Cross-presentation 
Although MHC class I is mainly loaded with the peptides, derived from cytosolic 
proteins, CD8+ T-cell responses are also induced by the exogenous pathogens. These 
pathogens enter the cell via endocytic pathway and thus theoretically should be 
restricted to the MHC class II antigen presentation pathway. The process allowing 
exogenous antigens to be presented in the context of MHC class I is called cross-
presentation. 
The ability to cross-present exogenous antigens in vivo was demonstrated mainly for 
DC and macrophages. However, other endocytic cells, including B-cells and 
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keratinocytes were shown in vitro to cross-present exogenous antigens on MHC class 
I with low efficiency [54, 55]. 
The molecular mechanism of cross-presentation is not yet completely understood. 
One possible mechanism of cross-presentation is described by the exchange model. 
According to this model, MHC class I can be internalized from the cell surface 
following monoubiquitination [56], and subsequently included into multivesicular 
bodies. In this compartment, MHC class I is colocalized with MHC class II [57]. 
Cross-presentation then can occur by exchange of MHC class I associated peptides for 
the antigens newly generated by proteolysis in the endosomal compartment. The 
endosomal antigen exchange pathway is dependent on lysosomal degradation. This 
pathway was shown to contribute at least in part to the cross-presentation of some 
antigens [58, 59]. However, the antigens that are cross-presented on MHC class I 
according to this model are produced by different proteolytic systems and in different 
conditions than antigens that are processed by the classical MHC class I pathway. 
This may in some cases result in a different pool of antigens. Usually, non-
hematopoietic cells process antigens only via the classical MHC class I pathway. 
Thus, the antigens produced by exchange will not contribute much to an efficient 
CD8+ T-cell response against exogenous pathogens restricted to the endocytic 
pathway and targeting non-hematopoietic cells. Moreover, in other studies, cross-
presentation in DC was shown not to be influenced by inhibitors of lysosomal 
proteolysis or by the inhibitor of lysosomal acidification chloroquin [54, 60-62]. 
Instead, cross-presentation was shown to be dependent on the classical MHC class I 
antigen presentation pathway. In these studies, cross-presentation was highly sensitive 
to proteasomal inhibitors [62, 63] and also strictly depended on TAP function, as it 
was completely abrogated in TAP-deficient cell-lines and mutant mice [63, 64] These 
data suggest that there is more than one mechanism involved in antigen cross-
presentation. 
Experimental evidence suggests that exogenous antigens can successfully reach the 
cytoplasm [61, 65, 66]. The molecular mechanism of this process is yet unclear. One 
protein proposed to be responsible for ‘retrotranslocation’ of exogenous antigens is 
Sec61. Sec61 cotranslationally inserts secretory and transmembrane proteins into the 
ER but also shuttles misfolded and unstable proteins back to cytosol for proteolysis by 
proteasomes (ER associated degradation) [67-69]. Sec61 was indeed found in 
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phagosomes [70] and associated with internalized exogenous antigens in the 
endosomal compartment [71]. Moreover, cross-presentation of exogenous antigens 
was inhibited upon downregulation of Sec61 levels by RNA interference [71]. Apart 
from Sec61, phagosomes were shown to contain other ER associated factors, that are 
necessary for MHC class I loading. These include TAP, MHC class I molecules, 
calnexin, calreticulin and tapasin, as well as an ER aminopeptidase [71-73]. One 
potential mechanism that could explain the phagosomal localization of the ER 
proteins is ER-mediated phagocytosis. Gagnon and colleagues reported that in mouse 
macrophage cell lines, the ER can fuse with early forming phagosomes, donating a 
portion of its membranes together with ER-resident proteins [70]. As a result, 
phagosomes contain all the proteins needed for MHC class I loading. Additionally, 
proteasomes were also shown to be associated with the cytoplasmic surface of the 
phagosomes [74]. Several studies suggested that the cross-presented peptides are 
generated in the cytosol, probably by phagosome associated proteasomes, and are 
immediately transferred back to be loaded on the MHC class I molecules inside the 
phagosomes [72-74]. Alternatively, phagosomes may fuse with the ER at some point, 
releasing soluble antigens into the ER, so that the MHC class I loading occurs inside 
the ER. Consistent with this model are the findings that some exogenous soluble 
proteins after their internalization can access the ER in a nondegraded form [75]. 
Cross-presentation is a very important mechanism that enables the immune system to 
react efficiently with both, CD4+ and CD8+ T-cell responses to infections or somatic 
mutations, without antigen presenting cells having to be directly infected or 
endogenously express the antigens. 
1.2.3 DC maturation and function 
DC maturation is a complex process, converting them from weakly 
immunostimulating cells specialized in antigen uptake into potent initiators of both 
humoral and cellular immune responses. Maturation is accompanied by 
downregulation of antigen uptake by phago- and endocytosis, increase of surface 
expression of antigen-presenting molecules and co-stimulatory molecules, production 
of pro-inflammatory cytokines and acquiring the ability to respond to lymph node-
directing chemokines.  
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1.2.3.1 Maturation stimuli: The danger model and intracellular signaling associated 
with DC maturation 
According to the danger model proposed by Matzinger [76], the immune system is 
activated by so called “danger signals”. These are the signals derived from pathogens 
or injured cells, exposed to pathogens, toxins or mechanical damage. Danger signals 
can induce DC maturation resulting in the subsequent activation of innate and 
adaptive immune responses. Main classes of signals that induce DC maturation are 
reviewed below. 
Toll-like receptor signaling 
Toll-like receptors (TLR) are a big family of evolutionary conserved pattern 
recognition receptors (PRR) (reviewed in [77]). 11 mouse and 10 human members of 
this family have been identified so far. TLR share a cytoplasmic domain with IL-1 
receptors, which is known as toll/IL-1R (TIR) domain. The extracellular domain of 
TLRs contains 24-29 tandem copies of leucine-rich repeats. TLRs recognize a broad 
range of molecular patterns, including lipopolysaccharides (TLR4) [78], lipoproteins, 
glycolipids and peptidoglycans (TLR2) [79-81], double-stranded RNA (TLR3) [82], 
single-stranded RNA (TLR7 and 8) [83] and CpG-containing DNA (TLR9) [84]. 
TLR1, TLR2 and TLR4 are located on the cell surface and are recruited to the 
phagosomes upon ligand binding. In contrast, TLR3, TLR7 and TLR9, which 
recognize RNA and DNA, are not expressed on the cell surface. Localization to the 
ER and recruitment to the endosomal/lysosomal compartment upon stimulation with 
CpG-containing DNA was demonstrated for TLR9 [85]. 
After ligand binding, TLRs dimerize and recruit the adaptor molecule MyD88 
(myeloid differentiation primary response protein 88). MyD88, in turn, recruits IL-
1R-associated kinase 4 (IRAK4). Upon binding of MyD88 to IRAK4, IRAK4 
phosphorylates IRAK1, which then becomes active. IRAK1 additionally 
autophosphorylates residues in its N-terminus, thus enabling TNF-receptor associated 
factor 6 (TRAF6) to bind to this complex. The IRAK1-TRAF6 complex dissociates 
from the receptor and initiates a series of events that lead to TGF-β-activated kinase 1 
(TAK1) activation. TAK1 subsequently activates IKK (IκB kinases). IKK 
phosphorylate IκB (inhibitor of NF-κB) thus targeting it to proteasomal degradation. 
IκB degradation results in the release of NF-κB and the consequent transcription of 
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NF-κB target genes. Furthermore, active TAK1 activates mitogen-activated protein 
kinases (MAPK) [77]. 
Apart from the MyD88-dependent pathway, an MyD88-independent pathway plays a 
role in the response to some TLRs, e.g. TLR3 and TLR4. The MyD88-independent 
pathway involves other adaptor molecules (TIR-domain-containing adaptor protein 
inducing IFN-β, TRIF, and TRIF-related adaptor molecule, TRAM). This pathway 
leads to activation of IFN-regulatory factor 3 (IRF3) [86] as well as NF-κB (although 
with a delayed kinetics as compared to the MyD88-dependent pathway) [87]. IRF3 
and NF-κB activation results in IFN-β production, which in an autocrine manner 
activates the transcription of a number of IFN-inducible genes, including late 
IFNα/IFNβ production [88]. 
TLRs play an important role in the recognition of foreign pathogens, including 
bacteria, viruses and fungi. Myeloid DC express TLR1-6 and TLR8, whereas 
plasmacytoid DC express TLR7 and 9 [89]. TLR signaling leads to DC maturation. In 
response to TLR-ligands, DC upregulate the expression of surface co-stimulatory 
molecules (e.g. CD40, CD80 and CD86). This can occur via both, MyD88-dependent 
and MyD88-independent pathways [88, 90]. In contrast, TLR-mediated production of 
pro-inflammatory cytokines is controlled by the MyD88-dependent pathway, although 
the second pathway can enhance pro-inflammatory cytokine production [87, 91]. 
Thus, expression of co-stimulatory molecules and production of pro-inflammatory 
cytokines are differentially regulated during TLR signaling. 
NOD-signaling 
Another class of receptors, the nucleotide binding oligomerization domain (NOD) 
family of proteins, is involved in TLR-independent recognition of certain intracellular 
pathogens (reviewed in [92]). They are located in the cytoplasm and recognize 
bacterial peptidoglycan structures. The human NOD-family includes 20 proteins. One 
of the molecules that is expressed in DC and is involved in pathogen recognition is 
NOD2. NOD2 recognizes bacterial lipopolysaccharide (LPS) and peptidoglycan. 
Interaction of NOD2 with its ligands results in NF-κB activation as well as activation 
of a number of caspases. Recent analyses have indicated that the essential structure 
within peptidoglycan for the recognition by NOD2 is muramyldipeptide (MDP). MDP 
is present in peptidoglycans from almost all Gram-positive and Gram–negative 
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bacteria. Upon activation with MDP, DC secrete pro-inflammatory cytokines, 
including IL6 and IL12 [93]. Moreover, DC respond to MDP stimulation by 
upregulating surface expression of co-stimulatory molecules [93], indicating that 
NOD2 can activate DC in a manner similar to TLR. 
Fc-receptor-signaling  
Immune complexes containing antigens opsonised by immunoglobulins (Ig) were also 
shown to promote DC maturation [94-96]. This is mediated by the Fc-receptor (FcR) 
family. The role of FcRs in human DC was recently reviewed by Bajtay et al [97]. 
Human DC express FcRs recognizing IgG, IgA and IgE isotypes (FcγR, FcαR and 
FcεR, respectively). FcRs can be functionally divided into activating (i.e. FcγRI, 
FcγRIIA, FcγRIIIA) and inhibitory receptors (i.e. FcγRIIB). The activating FcRs 
contain an immunoreceptor tyrosine-based activation motif (ITAM) whereas the 
inhibitory FcRs contain an immunoreceptor tyrosine-based inhibition motif (ITIM). 
Crosslinking of the activating FcRs by immune complexes leads to tyrosine 
phosphorylation of ITAM. The signal cascade initiated by this event results in 
recruitment of phoshatidylinositol-3 kinase (PI3K) and phospholipase-Cγ (PLCγ) 
which trigger protein kinase C (PKC) activation and sustained calcium elevation [98]. 
Crosslinking of the activating FcγRIIA induces phagocytosis, upregulation of DC 
maturation markers and enhances efficient antigen cross-presentation to T-cells [94-
96]. In contrast, the ITIM-containing FcγRIIB inhibits DC maturation, as suggested 
by studies of FcγRIIB-deficient mice that showed enhanced potential to generate T-
cell responses [99]. This was further supported by in vitro experiments with the 
human DC by Dhodapkar et al. Blocking immune complex binding to FcγRIIB by 
monoclonal antibodies was sufficient to induce DC maturation and IL12 secretion in 
response to immune complexes normally present in plasma [100]. 
Cytokine-induced maturation 
Pro-inflammatory cytokines, such as TNF-α  [101, 102] and IL-1β [103], were 
demonstrated to induce maturation of DC. Other cytokines, including IL-6 [104], 
IFN-α [105] and prostaglandin E2 (PGE2) [104, 106] can synergize with TNF-α and 
IL-1β promoting DC-maturation in vitro.  
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T-cell dependent maturation: CD40/CD40L interaction 
CD40 is a type I transmembrane glycoprotein cell surface receptor belonging to the 
tumor necrosis factor α (TNF-α) receptor family. Its ligand, CD40L (CD154), is a 
type II integral membrane protein expressed on activated T cells [107], activated B 
cells [108], and activated platelets [109]. Stimulation through CD40 results in a 
complex series of events within an APC. Engagement of CD40 by CD40L leads to 
multimerization of CD40 and subsequent recruitment of TNF receptor–associated 
factors (TRAFs) to the cytoplasmic tail [110]. TRAF binding results in formation of a 
signaling complex that includes multiple kinases, such as NF-κB inducing kinase 
(NIK), receptor interacting protein (RIP), PI3K, members of the mitogen-activated 
protein kinase (MAPK) family and possibly others. These kinases then initiate a 
downstream cascade of signaling events, resulting in the activation of the NF-κB and, 
possibly NF-AT and CREB transcription factors (reviewed in [111]). Crosslinking of 
CD40 in iDC results in upregulation of DC maturation markers [112, 113], production 
of pro-inflammatory cytokines (i.e. IL-12p70 [114] and TNF-α [113]) and 
chemokines [115] as well as in prolonged DC survival [116]. 
1.2.3.2 Maturation induced changes in DC phenotype and functions 
Antigen presentation 
MHC class II presentation is highly regulated in DC. Following activation, iDC 
upregulate MHC-II expression. In iDC, MHC class II is mainly detected in the 
endosomal compartment, whereas after stimulation, more MHC class II molecules are 
expressed on the cell surface. Two models were proposed to explain how MHC class 
II is regulated. The first model suggests that peptide generation and formation of 
peptide-MHC class II complexes is more efficient in mature as compared to immature 
DC. The other model proposes that increase of surface MHC class II expression in the 
mature DC state is achieved by a disruption of the peptide-MHC complex turnover. 
Peptide-MHC complexes are then retained in the plasma membrane (reviewed in 
[117]). Endosomal protein degradation and peptide-MHC complex formation was 
shown to be enhanced during DC maturation. Maturation is associated with increased 
activity of lysosomal hydrolases [118] due to increased acidification of lysosomes. 
Maturation is also accompanied by increased invariant chain degradation by cathepsin 
S due to downregulation of the cathepsin S inhibitor, cystatin C [119]. On the other 
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hand, iDC and mature DC differ in the rate of MHC class II turnover. In iDC, peptide-
MHC class II complexes are only transiently expressed on the cell surface and then 
rapidly internalized. In contrast, in mature DC peptide-MHC class II complexes are 
retained on the plasma membrane [120]. Therefore, the available experimental 
evidence suggests that both mechanisms may contribute to the regulation of MHC 
class II. 
Although peptide-MHC class I complex formation is more efficient in iDC, the 
surface expression levels of loaded MHC class I molecules is increased upon 
maturation. This results from increased synthesis and lower turnover of peptide-MHC 
complexes in mature as compared to immature DC [120, 121]. 
Cross-presentation was also shown to be regulated upon DC maturation [94, 122, 
123]. The enhancement of cross-presentation could be a result of the increased 
synthesis of MHC class I [120, 121] and other components of peptide-processing 
machinery [123]. However, not all the signals that enhance synthesis of MHC class I 
result in increased cross-presentation [122], suggesting the existence of additional 
mechanism of regulation of cross-presentation [117]. 
Adhesion molecules and co-stimulatory molecules 
During maturation, DC upregulate surface expression of a number of molecules. 
These include co-stimulatory molecules CD40, CD70, CD80, CD83 and CD86 and 
OX40L, most of which are involved in bidirectional signaling between DC and T-
cells. 
CD80 and CD86 are members of the B7 receptor family. They provide co-stimulation 
of T-lymphocytes via CD28 signaling. CD28 is constitutively expressed on T-cells. 
CD28 signaling influences the threshold for T-cell activation and significantly 
decreases the number of TCR engagements needed for effective T-cell activation 
[124]. Ligation of CD28 by its ligands, CD80 (B7-1) and CD86 (B7-2), synergizes 
TCR signaling and leads to increased production of IL-2, proliferation, and enhanced 
survival of T-cells (reviewed in [125]). 
Co-stimulatory functions of CD83 were recently reported by Hirano et al. They 
showed that CD83 ligand (CD83L) expression is upregulated on CD4+ and CD8+ T-
cells. This upregulation requires CD28 co-stimulation. Using artificial APC 
expressing CD80 and CD83 alone or in combination, Hirano N. and co-workers 
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demonstrated that CD83:CD83L signaling specifically supported priming and 
expansion of naïve CD8+ T-cells. Moreover, engagement of CD83 enabled long-term 
survival of in vitro generated antigen-specific CTL-cultures by enhancing 
proliferation and inhibiting apoptosis [126]. 
Mature DC also express several adhesion molecules, including CD2, CD11a, CD54 
(ICAM-1), CD58 (LFA-3) and several integrins. They are believed to play a role in 
attracting the T-cells and, together with other co-stimulatory molecules, are involved 
in formation of the immune synapse between T–cells and DC [127]. 
Cytokine production 
Different maturation stimuli may induce cytokine secretion by DC. The cytokine 
profile can be different depending on the type of stimuli and the DC subtype. For 
example, high levels of type I IFN (IFNα/β) are mainly produced by plasmacytoid 
DC. Major pro-inflammatory cytokines that can be secreted by mature DC include IL-
12p70 [114, 128], IL-6, IL-1β and TNF-α [113, 129, 130]. Human monocyte-derived 
DC are also capable of producing the anti-inflammatory cytokine IL-10 in response to 
maturation stimuli [131, 132]. The profile of DC-secreted cytokines plays an 
important role in defining the type of immune response that will be induced. 
Chemokines, chemokine receptors and migration 
In order to prime T-cell responses, DC have to reach secondary lymphoid organs. The 
main receptor that mediates recruitment of DC to the lymph nodes is CCR7. The 
CCR7 ligands CCL19 (MIP-3β) and CCL21 (6Ckine) are secreted by lymphatic 
endothelial cells and lymph node stromal cells [133-135]. Expression of CCR7 is 
upregulated by most maturation-inducing stimuli. Maturation is also accompanied by 
downregulation of chemokine receptors responsible for tissue retention of DC (i.e. 
CCR1, CCR5) [136]. 
The expression of CCR7 is necessary but not sufficient for migration. A variety of 
other factors were implicated to influence migration. This includes lipid mediators, 
prostaglandins, adhesion molecules and matrix metalloproteinases (as reviewed in 
[137]). 
1. Introduction 
 16
Mature DC also start to secrete a number of chemokines, such as TARC, MDC, IP-10 
that recruit different T-cell subtypes [138]. In addition, mature DC can secrete 
RANTES, MIP-1α and MIP-1β that can attract monocytes [138]. 
1.2.4 Adaptive differentiation of DC 
Human monocyte-derived dendritic cells (MoDC) respond to activation stimuli with 
an adaptive differentiation program that allows the development of diverse functional 
DC phenotypes. Depending on the type, strength and persistence of the activation 
stimulus [139] DC can acquire a pro-inflammatory, a migratory, or a mixed 
phenotype. For instance, DC activated in the presence of PGE2 become migratory 
DC: they are unable to secrete inflammatory IL-12p70, but can migrate towards 
lymph node-directing chemokines (i.e. CCR7 ligands). In contrast, CD40L-activated 
DC acquire a pro-inflammatory function: they secrete large amounts of cytokines, 
especially IL-12p70, IL6 and TNF, but are incapable of migrating toward CCR7 
ligands [139-141]. DC activated with live pathogens (i.e. E.coli) can accomplish both 
functions – they secrete high levels of pro-inflammatory cytokines and migrate 
towards CCR7 ligands [139]. IL-12p70 production requires persistent stimulation 
whereas for migration, weak and non-persistent signals are sufficient. Furthermore, 
migration is inhibited by persistent CD40L signaling [139]. Migration and cytokine 
secretion are independently regulated by a network of extra- and intracellular factors 
and pathways [141]. IL-12p70 production is enhanced by IL-4, IL-1β [142], IFN-γ 
and IFN-α [143, 144] and inhibited by IL10 [145], PGE2 [140, 146] or cyclic 
adenosine monophosphate (cAMP) [147, 148]. Both, ERK1/2 and p38 MAPK activity 
are needed for IL-12p70 secretion by human monocyte-derived DC, whereas PI3K 
inhibited IL-12p70 production [139, 141]. Migration of DC towards lymph nodes is 
enhanced by PGE2 and cAMP and requires p38 MAPK activity, whereas ERK1/2 
inhibits the migratory capacity of DC [139]. Our group suggested that the intracellular 
players comprising the molecular network required for a specific function are 
organized as a functional unit or “module” (signal response module, SRM) [141]. 
Despite accumulating knowledge of factors influencing any given functional module, 
principles that govern the signalling network operation remain to be defined. 
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1.2.5 DC interactions with different immune cell types 
1.2.5.1 DC-T-cell interactions 
One of the main functions of DC is to induce T-cell responses. The outcome of T-cell-
DC interaction depends on the functional state of DC (i.e. MHC class I and II 
expression level, expression of co-stimulatory molecules and secreted cytokines). DC 
are capable of priming naïve T-cells to proliferate and differentiate into effector and 
memory T-cells as well as polarizing immune reactions towards type 1 or type 2 
responses. However, DC are also involved in the generation of T-cell tolerance either 
by inducing abortive proliferation and anergy of antigen-reactive T-cells or by 
activating regulatory T-cell subsets. 
Priming of naïve T-cells: strength and persistence of the signal 
The efficiency of T-cell priming depends on strength and persistence of the priming 
signal. Immature DC are unable to form stable conjugates with T-cells and thus are 
not efficient in priming T-cell responses [149, 150]. This is probably due to the low 
levels of MHC expression and the absence of co-stimulation in iDC. Immature DC 
form short, transient contacts with T-cells, which result in abortive proliferation and 
subsequent deletion of antigen-specific T-cells [149, 151]. Several studies on mouse 
and human T-cells demonstrated that prolonged APC-T-cell interaction in the 
presence of co-stimulation is necessary to achieve efficient priming of naïve T-cells 
[149, 151, 152]. In vivo imaging of lymphocytes trafficking in mouse lymph nodes 
showed that mature DC acquire the ability to form stable contacts with T-cells within 
15-20 hours after activation [151]. These contacts are maintained for several hours 
resulting in generation of effector T-cells [151, 152]. Concentration of MHC-antigen 
complexes and co-stimulation contribute to the strength and persistence of the priming 
signal. Indeed, Bousso et al showed that the duration of DC-T-cell interaction in vivo 
correlated with the antigen density [152]. As mentioned before, co-stimulatory CD28 
signal lowered the threshold for the number of TCR-MHC interactions needed for T-
cell activation [124]. Other co-stimulatory molecules, including members of the tumor 
necrosis factor receptor (TNFR) family, such as CD27 and OX40, are also involved in 
both priming naïve T-cells and sustaining long-lived T-cell immunity (reviewed in 
[153]). 
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Polarization of immune responses: Th1 versus Th2  
T-helper type 1 effector cells (Th1) secrete high levels of IFN-γ and IL-2 and mediate 
mainly cellular immune responses. T-helper type 2 effector cells (Th2) produce 
mainly IL4, IL5, IL10 and IL13, support humoral immune responses and 
downregulate Th1 responses. Depending on the subtype and the cytokine profile, DC 
can direct T-cells towards type 1 or type 2 responses.  
One of the main type 1-polarizing cytokines is IL-12p70. Different types of pathogens 
and pathogen-derived products can induce DC to secrete high levels of IL-12p70. This 
includes Leishmania [154], some types of live bacteria [155-157] and live viruses 
[158] as well as their derivatives. Additionally, DC can secrete IL-12p70 in response 
to CD40L activation [142-144]. The production of IL-12p70 can be enhanced by 
various cytokines, e.g. IFN-α and IFN-γ [143, 144], IL-1β and IL-4 [142]. Other 
cytokines, produced by DC, such as IL-23, IL27, IL18 and type I IFN can synergize 
with IL-12 to promote Th1 responses (reviewed in [159]). 
Th2 polarizing signals are less well defined than Th1-directing signals. Absence of 
IL-12 is a prerequisite for the induction of Th2 responses. Some products released by 
parasites, e.g. Schistosoma mansoni [160] are known to trigger TLR2 and promote a 
Th2 response. Additionally, IL-4, OX-40L and several chemokines (e.g. MCP-1) are 
proposed to play a role in Th2 polarization [159]. 
Inducing tolerance 
DC are capable of inducing tolerance by at least two different mechanisms. Immature 
DC can induce abortive proliferation and subsequent depletion and/or anergy of 
antigen-recognizing T-cells [149, 151]. Additionally, both, iDC [161] and mature DC 
[162], were reported to activate regulatory T-cells in mouse and human systems. IL-
10 was implicated as one of the main factors involved in the induction of regulatory 
T-cells. However, several other molecules, including inhibitory members of the B7 
family (e.g. PD-L1, PD-L2, B7-H3 and B7-H4) and the immunoglobulin-like 
transcripts 3 and 4 (ILT3 and ILT4) may also be involved in this process (reviewed in 
[159]). DC can be modulated to become tolerogenic in culture by IL-10, TGF-β or 
corticosteroids [163]. Depletion of antigen-recognizing T-cells as well as activation of 
regulatory T-cell subsets by DC is an important mechanism of maintaining peripheral 
tolerance to self antigens. 
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1.3 DC-Based Cancer Immunotherapy 
DC have the unique capacity to stimulate both humoral and cell-mediated immune 
responses. Therefore, they are attractive candidates for active vaccination strategies. 
The ability of DC-based vaccines to induce effective immune responses is currently 
being evaluated in mouse models as well as in human clinical studies. One of the 
main clinical applications of DC-based vaccinations is immunotherapy of cancer. 
The two main sources of DC used in clinical applications are 1) proliferating CD34+ 
precursors and 2) non-proliferating CD14+monocytes. CD34+ DC precursors can be 
separated from bone marrow or peripheral blood following stem cell mobilization by 
Flt3 or granulocyte-colony stimulating factor (G-CSF) administration. CD34+ cells 
can then be differentiated into DC by culturing with different cytokine combinations, 
including TNF-α, granulocyte macrophage-colony stimulating factor (GM-CSF), Flt3 
ligand and CD40L. CD14+ monocytes can be obtained in large amounts from 
peripheral blood. Immature DC can be generated from CD14+ monocytes by culturing 
for 5-7 days in the presence of GM-CSF and IL-4. Immature DC can further be 
induced to mature by different activation stimuli. 
1.3.1 Antigen loading strategies 
The most common strategy used for antigen loading of DC is pulsing them with 
synthetic peptides. These peptides represent epitopes derived from tumor-proteins. 
Synthetic peptides are easy to produce on large scale and the antigen-loading process 
can be well-controlled. Moreover, the immune response will be mainly epitope-
specific and is easy to monitor. However, this approach has certain disadvantages. 
The application is restricted by the patient’s HLA type: tumor-derived epitopes have 
to be defined for individual HLA alleles. Moreover, this approach has mainly focused 
on inducing CD8+ T-cells, ignoring that the CD4+ help is often needed for efficient 
anti-tumor response [164]. The need for CD4+ help, however, can be overcome 
depending on the type of DC maturation stimuli used [165-167]. 
Several clinical studies employed DC pulsed with tumor-derived peptides. These 
studies were mainly performed on patients with advanced metastatic melanoma [168-
172], as a number of melanoma-associated antigens have been well characterized. 
Metastatic prostate, breast and ovarian cancers were also targeted by DC-peptide 
therapy [173, 174]. In these studies, expansion of antigen-specific cytotoxic CD8+ T-
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lymphocytes occurred in a significant fraction of patients. Clinical responses could be 
detected in approx. 30% of patients. Recently, Tuettenberg and coworkers 
demonstrated induction of long-lived tumor antigen-specific T-cells in stage II 
melanoma patients after vaccination with DC pulsed with MelanA/MART-1 peptide. 
10 out of 13 patients after the vaccination remained disease-free with the follow-up 
period of 21-33 months [175]. 
Importantly, epitope-spreading after vaccination with a single peptide has been 
observed, demonstrating the generation of immune responses against tumor antigens 
different from those used for vaccination [173, 176, 177]. 
Purified or recombinant proteins are used as an alternative strategy for DC loading 
with tumor-specific antigens [178, 179]. This approach has the following advantages: 
1) the need of characterization of the individual epitopes is circumvented; 2) no 
selection for the patient’s HLA type is needed; 3) the protein contains epitopes for 
both classes of MHC and thus CD4+ and CD8+ can be stimulated simultaneously. The 
protein is most efficiently uptaken by immature DC. However, for efficient T-cell 
stimulation, fully mature DC are required. Therefore, the DC maturation stage has to 
be carefully controlled. Moreover, it is difficult to control efficiency of DC loading if 
the exact epitopes are not known. The same applies for the monitoring of immune 
responses after vaccination.  
Other strategies of DC loading with a broad spectrum of tumor-derived antigens 
include entire tumor cell lysates [170, 180], apoptotic tumor cells or the fusion of DC 
with tumor cells [181, 182]. This allows to generate both, CD4+ and CD8+ T-cell 
responses simultaneously against a broad range of tumor associated antigens. This 
strategy may also reduce tumor escape from immune recognition by clonal selection 
of antigen-negative tumor cells, which occurs upon immunization with a limited 
number of epitopes. This strategy, however, is limited by the availability of sufficient 
tumor tissue. The potential risk of inducing autoimmunity against shared self-antigens 
should also be considered.  
Another way of antigen loading is DC transfection with RNA (tumor antigen-specific 
or total tumor RNA) or DNA (e.g. recombinant viruses, encoding tumor antigens). 
This method, although efficient [183-186], is technically more demanding than the 
other strategies mentioned above. 
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1.3.2 Enhancing the efficiency of anti-tumor vaccines by manipulating DC in 
vitro 
The efficiency of a DC-based vaccination depends on the maturation state and 
functional properties of the DC. The first recognition of the importance of DC 
maturation state came from several clinical studies that demonstrated that immature, 
but not mature DC can induce antigen-specific inhibition of effector T-cell function 
and induction of regulatory T-cells [161, 187, 188]. Mature DC, however, depending 
on the time of activation, may have already exhausted the production of cytokines, 
such as IL-12p70, at the time they reach lymph nodes, and therefore fail to activate an 
efficient immune response [189]. The type of maturation stimuli used for the 
activation of DC also matters for the outcome of vaccination. For example, Bullock 
and coworkers demonstrated that DC preactivated via CD40L and, to a less extent, via 
TLR4 or TLR9 ligands were capable of activating CD8+ T-cells independently of 
CD4+ help. They could correlate this effect with the surface expression of CD70 
costimulatory molecule, which was not induced by other activation stimuli [165].  
The dose and frequency of vaccination is another variable that effects the induction 
and maintenance of T-cell responses. Several mouse experiments show that weekly 
administration of peptide-pulsed DC led to diminished antigen-specific T-cell activity 
[190] either due to clonal exhaustion of expanded T-cells or due to rapid lysis of 
antigen-pulsed DC by CD8+ T-cells [191]. Therefore, the frequency of vaccine 
administration has to be optimized to induce persistent antigen-specific responses in 
tumor patients.  
Another important issue for using DC as adjuvants for vaccination is the route of 
delivery of DC. Several mouse and human studies reported dependence of vaccination 
efficiency on the route of delivery of DC. Intradermal or subcutaneous injections were 
found to be superior as compared to intravenous injection [190, 192]. The dependence 
of the vaccination efficiency on the route of DC delivery could reflect the ability of ex 
vivo activated DC to migrate towards lymph nodes. It was recently estimated in 
human and mouse experiments, that upon intradermal injection approximately 5% of 
DC reach the lymph nodes [193, 194]. Therefore, enhancing the migration ability of 
DC could also improve the vaccination efficiency. 
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DC-based vaccination is a rapidly developing field of immunotherapy. Early clinical 
trials and mouse models provided a proof of principle and established general safety 
of this approach. The capacity of DC to direct cancer-specific responses was 
demonstrated in a number of mouse and human trials. Intensive research is focused on 
improving the effectiveness of DC-based vaccines. The generation of successful anti-
tumor vaccines requires a better understanding of the fundamental biology of DC as 
well as establishing and characterization of tumor-associated antigens that can be used 
for vaccinations.  
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1.4 Motivation and scope of the thesis 
The first part of this work is focused on identification and characterization of new 
potential MHC class I antigens for active vaccination against hematological 
malignancies in context of stem cell transplantation. 
Hematological malignancies are among the leading forms of cancer. Autologous and 
allogeneic stem cell transplantation (SCT) is often used as a therapy mainly for 
patients with hematological malignancies who relapsed after standard chemotherapy, 
or even as a primary therapy, in the case of multiple myeloma. However, additional 
therapeutic strategies are required to improve clinical outcome of conventional 
therapeutic approaches. One possibility to increase the therapeutic effect is provided 
by immunotherapy after SCT. 
The most serious complication after allogeneic SCT is graft versus host disease 
(GvHD). Although GvHD is an important cause of mortality after allogeneic SCT, 
patients developing GvHD achieve higher rates of disease remission, than patients 
without GvHD [195]. This suggests that GvHD is accompanied by immune reaction 
against malignant cells (graft vs leukemia/lymphoma, GvL). T-lymphocytes play an 
important role in both GvHD and GvL after allogeneic SCT [195]. Although little is 
known about antigens that are recognized by T-cells, GvHD and GvL effects 
presumably involve polymorphism of normal cellular proteins. These proteins are 
present on both normal and malignant stem cells but are not shared between recipient 
and donor. Peptides derived from polymorphic regions of these proteins can be 
presented in the context of HLA and are named minor histocompatibility antigens. 
Minor histocompatibility antigens (mHA) specifically expressed on recipients’ cells 
can be recognized by donor T-cells. In the case of complete MHC match between 
donor and recipient, GvHD is considered to be the consequence of immune responses 
against mHA, specifically expressed on recipients’ cells. These mHA have a wide 
tissue distribution, including skin, liver, and gastrointestinal tissues. In contrast, 
antigens that are expressed only by blood cells could induce an exclusive graft vs 
hematopoietic (GvH) reaction [196] that can include putative GvL effect. As the 
hematopoietic system of recipient is replaced by donor stem cells, this immune 
reaction will not induce a severe clinical pathology. Therefore, mHA that are 
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expressed exclusively by hematopoietic cells represent attractive candidates for 
vaccination after SCT. 
In unrelated allogeneic SCT, the majority of HLA-A, -B, -C and HLA-DR-matched 
recipient-donor pairs show mismatches in HLA-DP [197]. Single allele mismatches in 
HLA-DP do not appear to influence the risk of acute GvHD, whereas patients 
mismatched for two HLA-DP alleles have a significantly increased risk of GvHD 
[198], suggesting that immune responses against HLA-DP could be involved in 
GvHD development. Indeed, a CD4+ response against HLA-DP was previously 
demonstrated in a patient [199, 200]. However, the major role in GvHD and GvL is 
attributed to CD8+ T-cells. Therefore, in the context of HLA-DP-mismatched 
allogeneic SCT, the induction of donor CD8+ T-cells specifically recognizing MHC 
class I antigens, derived from polymorphic region of the recipients’ HLA-DP variant 
can represent a promising therapeutical approach. 
A large subset of hematological cancers is represented by B-cell malignancies, 
including non-Hodgkin’s lymphomas and multiple myelomas. B-cell malignancies 
appear to be suitable candidate targets for immunotherapy approaches, as a number of 
surface markers are well characterized. These include markers that are tumor-specific 
or shared by B–cell malignancies and normal B-cells. 
Immunotherapy against B-cell malignancies may include monoclonal antibodies as 
well as T-cell therapy. Most studies on T-cell mediated therapy have targeted 
idiotypic sequences of immunoglobulin molecule. B-cell malignancies are usually 
derived from a single expanded B-cell clone, which expresses an immunoglobulin (Ig) 
with a unique idiotype (variable regions of Ig). Therefore, the idiotype can be 
regarded as a tumor-specific antigen. However, idiotype vaccine has to be produced 
individually for each patient. The alternative approach is to vaccinate against the 
isotype (i.e. heavy chain constant regions) of the Ig expressed on malignant cells. Ig-
isotypes are not unique for the individual B-cell malignancy but are shared by many 
patients. An immune response against immunoglobulin isotypes may lead to 
elimination of malignant cells, as well as target a subset of B-cells and their 
progenitors. Thus, antigens, derived from immunoglobulin constant regions represent 
potential targets for vaccination against B-cell malignancies. 
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The aim of the first part of this study was to identify and characterize antigens derived 
from HLA-DP alleles and from Ig constant regions as potential targets for vaccination 
after SCT. 
The generation of successful anti-tumor DC-based vaccines requires better 
understanding of the fundamental biology of DC. Therefore, the second part of this 
work is focused on the intracellular signaling pathways that regulate different 
functions of DC, in particular, glycogen synthase kinase 3 (GSK-3) pathway. 
GSK-3 is a multifunctional enzyme now recognized as a key regulator of numerous 
signaling pathways. Broad regulatory influence on cellular function: cellular structure, 
growth, motility, apoptosis. Due to its involvement in numerous signaling pathways, 
some of which are known to influence DC differentiation, GSK-3 is a candidate 
regulator of DC function. 
GSK-3 is linked to a diverse array of neurologic diseases, such as bipolar mood 
disease [201, 202], schizophrenia [203] and Alzheimer‘s disease [204], but also to 
non-neurologic diseases such as diabetes mellitus [205] and cancer [206-208]. 
Interestingly, most of these diseases are associated with immune deviations. 
Particularly, patients suffering from bipolar mood disorders and schizophrenia, who 
were reported to have an increased baseline GSK-3 activity [203], also have increased 
serum levels of pro-inflammatory cytokines such as IL-1β [209], IL-6 [210, 211] and 
IL12p70 [212]. Chronic treatment with the GSK-3 inhibitor lithium normalizes these 
deviations together with its therapeutic psychotropic effect. Furthermore, lithium has 
successfully been employed as a treatment in animal models of autoimmune diseases 
[213]. Recently, Martin et al. have demonstrated that GSK-3 inhibitors enhance IL-10 
secretion and inhibit IL-12p40, IL-6 and TNF-α secretion of human monocytes [214]. 
Furthermore, mice challenged with endotoxin could be rescued from death by septic 
shock using GSK-3 inhibitors [214]. 
Based on these observations, the purpose of the second part of this work was to 
investigate the role of GSK-3 in DC differentiation and function. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Antibodies 
Primary antibodies for flow cytometry: 
Anti human CD3-FITC   BD-Pharmingen, Heidelberg, Germany 
Anti human CD14-FITC   BD-Pharmingen  
Anti human CD19-PE   BD-Pharmingen 
Anti human CD80-FITC   BD-Pharmingen 
Anti human CD83-PE   BD-Pharmingen 
Anti human CD86-PE   BD-Pharmingen 
Anti human HLA-A2.1 (BB7.2), purified BD-Pharmingen 
Anti human HLA-ABC-FITC  BD-Pharmingen 
Anti human HLA-DR-PE   BD-Pharmingen 
Anti human IgD-PE    BD-Pharmingen 
Mouse isotype control IgG2a-FITC  BD-Pharmingen 
Mouse isotype control IgG1-PE  BD-Pharmingen 
Mouse isotype control IgG2a-PE  BD-Pharmingen 
Secondary antibodies for flow cytometry: 
Goat anti mouse IgG, PE-labeled  BD-Pharmingen 
Antibodies for enzyme-linked immunospot: 
Anti human IFN-γ (clone), purified  BD-Pharmingen 
Anti human IFN-γ (clone), biotinylated BD-Pharmingen 
  
Primary antibodies for Western Blot: 
phospho-Akt (Ser473)  Cell Signaling, Frankfurt am Main, Germany 
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phospho-GSK3α/β (Ser21/9)  Cell Signaling 
phospho-GSK3α/β (Tyr279/216) BioSource GmbH, Solingen, Germany 
β-catenin     Dianova GmbH, Hamburg, Germany  
p38      Santa Cruz, Heidelberg, Germany 
ERK-1/2     Santa Cruz 
β-actin     MP Biomedicals, Illkirch, France  
Secondary antibodies for Western Blot: 
HRP-conjugated antibodies to rabbit IgG   Santa Cruz 
2.1.2 ELISA sets, cytokines, chemokines and other materials  
Cytokine ELISA-sets (OptEIA brand) for IFN-γ, IL-6, IL-12p40, IL-12p70, TNF-α 
and IL-10 were purchased from BD Pharmingen. IL-23 ELISA kit was purchased 
from Hölzel Diagnostika, Cologne, Germany.  
The following cytokines were used: recombinant human (rh) GM-CSF (50 ng/ml, 
Berlex, Seattle, WA), rhTNF-α (10 ng/ml), rhIL-4 (50 U/ml) and IFN-α2a 
(2000 IU/ml) (all from PromoCell, Heidelberg, Germany). PGE2 (used at 1 µM final 
concentration) was purchased from MP Biomedicals, Costa Mesa, CA, USA. 
Lipopolysaccharide (LPS from E.coli 055:B5) was purchased from Calbiochem, 
Merck Biosciences GmBH, Darmstadt, Germany. CCL21 (6Ckine) was purchased 
from PromoCell and used in migration assays at 40 ng/ml. IL-2 (Proleukin®) was 
purchased from Pharmacy, University Clinic Heidelberg, Germany. IL-7 was 
purchased from PeproTech EC Ltd., London, UK. 
2.1.3 Protein kinase inhibitors 
The following GSK-inhibitors were used: LiCl (Calbiochem), SB216763 and 
SB415286 (Sigma-Aldrich, Taufkirchen, Germany), 1-azakenpaullone (Calbiochem). 
The membrane permeable synthetic cAMP analogue and activator of protein kinase A 
(PKA) (Sp-5,6-DCl-cBIMPS) was purchased from Biolog, Bremen, Germany. The 
PI3K inhibitor Wortmannin was purchased from Sigma-Aldrich. 
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2.1.4 Media 
RPMI 1640    Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
Iscove’s MDM   Sigma-Aldrich Chemie GmbH 
DMEM   Sigma-Aldrich Chemie GmbH 
2.1.5 Cell lines 
T2 (174 x CEM.T2) human HLA-A2+, MHC class II negative T-B 
lymphoblast hybrid was cultured in RPMI 
supplemented with 10% heat-inactivated fetal calf 
serum (FCS, Sigma-Aldrich Chemie GmbH), with 
60 mg/L penicillin G, 12.6 mg/L streptomycin, 2 mM 
L-glutamine. 
BHK-CD40L Baby Hamster Kidney (BHK) cells transfected with 
CD40L were cultured in DMEM containing 1 mM 
sodium pyruvate, 10% heat-inactivated FCS, with 
60 mg/L penicillin G, 12.6 mg/L streptomycin, 
500μg/ml G418, 2 mM L-glutamine. 
BHK-mock Baby Hamster Kidney (BHK) cell line transfected 
with an empty plasmid vector (pACF) was cultured 
similar to BHK-CD40L cells. 
IM9, KMS-12-BM and LP-1 human multiple myeloma cell lines were cultured in 
RPMI supplemented with 10% heat- inactivated FCS, 
with 60 mg/L penicillin G, 12.6 mg/L streptomycin, 
2 mM L-glutamine. 
T2 cell line (ATCC number CRL-1992™) was purchased from American Type 
Culture Collection (LGC Promochem GmbH, Wesel, Germany). BHK-CD40L and 
BHK-mock cell lines were a gift of Dr. E. Leo, University of Heidelberg. Human 
multiple myeloma cell lines (IM9, KMS-12-BM and LP-1) were kindly provided by 
Dr. M. Hundemer, University Clinic, Heidelberg. 
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2.1.6 Bacteria 
E. coli (XL-1) were cultured in LB-Broth* in a bacteria shaker (New Brunswick 
Scientific Co., Edison, USA) at 37 °C until an OD600 of 0.7. E. coli were then washed 
three times, resuspended in 60 mM CaCl2, 10 mM PIPES pH 7.0, 15% glycerol and 
frozen in 50 µl aliquots. Directly prior to activation, one E. coli aliquot was thawed, 
washed in double distilled water (dd H2O) and resuspended in 1 ml H2O. 20 µl of this 
solution was added to 1 ml of DC cultures, this concentration is referred to as 1:1. 
* LB-Broth medium   10 g NaCl  
10 g tryptone  
5 g yeast extract 
The mixture was dissolved in dd H2O to a final 
volume of 1 liter and autoclaved.  
2.1.7 Synthetic peptides 
Purified peptides were obtained as lyophilized powder from Dr. R. Pipkorn (Peptide 
synthesis lab, DKFZ, Heidelberg). Peptides were reconstituted in sterile DMSO to a 
concentration of 10mg/ml and then further diluted with PBS to the concentration of 1 
mg/ml. Reconstituted peptides were stored in 50-100 μl aliquots at -80°C. 
2.2 Methods 
2.2.1 Peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMC) were obtained from buffy coat 
preparations or directly from fresh blood of healthy donors from the Red Cross Blood 
Bank (Heidelberg, Germany). The blood was diluted 1:1 with sterile PBS and 
carefully layered on 15 ml of Biocoll solution (contains Ficoll®400, Biochrom AG, 
Berlin, Germany) in 50 ml Falcon tubes. The blood was then centrifuged for 20 min, 
at 1100 g at room temperature. Resulting interphase was transferred to fresh 50 ml 
tube and washed twice with sterile PBS. PBMC were then counted and either used 
immediately for preparation of CD14+ monocytes, B-cells or CTL lines, or frozen in 
freezing medium containing 45% FCS, 45% hetastarch (Sigma-Aldrich Chemie 
GmbH) and 10% DMSO (Merck Biosciences, Darmstadt, Germany).  
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2.2.2 CD14+ monocytes and monocyte-derived DC (MoDC) 
CD14+ monocytes were affinity purified from PBMC of healthy donors using the 
MACS CD14 isolation kit (Miltenyi Biotech, Germany) according to manufacturer’s 
instructions. CD14+ monocytes were either activated immediately or cultured at 0.5-
1×106 cells/ml in standard culture medium (RPMI with 10% heat-inactivated FCS, 
with 60 mg/L penicillin G, 12.6 mg/L streptomycin, 2 mM L-glutamine) 
supplemented with GM-CSF (50 ng/ml), and IL-4 (50 U/ml) in 24-well plates. By day 
5-7, MoDC represented more than 95% of cultured cells. On day 5-7, cells were 
washed and readjusted to 2-3×105 DC per ml. The following maturation-inducing 
factors were added: a mixture of pro-inflammatory cytokines (rhGM-CSF (50 ng/ml), 
rhTNF-α (10 ng/ml), IFN-α2a (2000 IU/ml) and PGE2 (1 µM)), BHK-CD40L (DC to 
BHK-CD40L ratio of 20:1), E. coli at high (1:1) and low (1:1000) concentrations or 
LPS (1 μg/ml). All cytokines and DC stimuli used in the present study have 
previously been tested in dose-titration analyses, and the concentrations used in the 
figures represent those found to be optimal. Dendritic cells and supernatants were 
harvested 24-36 hours after adding the maturation stimuli and analyzed for migration 
capacity, expression of surface markers and secretion of cytokines. Alternatively, DC 
were harvested after 6 hours of activation, washed twice with sterile PBS, pulsed with 
10μg/ml of synthetic peptide in serum-free RPMI medium (1 hour, 37°C) and used as 
stimulator cells for peptide-specific CTL lines. 
2.2.3 CD40-activated B-cells 
B-cell lines were generated from the PBMC of healthy donors based on the method 
published by Schultze (modified from [215]). B-cells were stimulated via CD40 using 
BHK cell line transfected with the human CD40L (BHK-CD40L). Expression of 
CD40L by BHK cells was confirmed by flow cytometry using an anti-CD40L mAb. 
BHK cells do not express human MHC class I and II and therefore do not activate 
CD4+ and CD8+ T-cells. For B-cell cultures, BHK-CD40L cells were irradiated 
(96Gy). PBMC (2×106 cells/ml) were cocultured in 6-well plates with BHK-CD40L 
(2×104 cells/ml) in presence of IL-4 (20U/ml) and 1×10-6 M cyclosporin A (CsA) in 
Iscove’s MDM supplemented with 10% pooled human serum, 1×ITS (Insulin-
Transferrin-Selenium supplement, Gibco®, Invitrogen GmbH, Karlsruhe, Germany), 
15μg/ml gentamycin at 37°C in a humidified 5% CO2 incubator.  The medium was 
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changed and the fresh irradiated BHK-CD40L cells were added every 3-4 days. The 
purity of B-cell population was assessed by flow cytometry using anti-CD19 and anti-
CD3 mAB starting from week three of culture.  
2.2.4 Peptide-specific CTL lines 
Peptide-specific CTL lines were generated from PBMC of healthy HLA-A2.1+ 
donors. CD8+ T-cells were purified from PBMC of healthy donors using MACS CD8 
isolation kit (Miltenyi Biotech, Germany) on day 0. Stimulator cells (γ-irradiated 
(100Gy) T2 cells or autologous, preactivated DC, as specified in text) were washed 
twice with PBS and preincubated with 10μg/ml of synthetic peptide in RPMI (serum 
free) for 1 hour at 37°C. CD8+ T-cells at the concentration of 1×106 cells/ml were 
cocultured with 2×105 stimulator cells/ml in T-cell medium (Iscove’s MDM 
containing 10% pooled heat-inactivated human serum, with 60 mg/L penicillin, 
12.6 mg/L streptomycin, 2 mM L-glutamine, 0.55 mM arginine, 0.24 mM asparagine) 
in 2 ml cultures in 24-well plates at 37°C, 10% CO2. On day 3, IL-2 and IL-7 were 
added to CTL cultures to the final concentration of 20 U/ml IL-2 and 10 ng/ml IL-7. 
Starting from day 7, the CTL cultures were harvested weekly, washed twice with 
PBS, adjusted to the concentration of 1×106 cells/ml and restimulated with peptide-
pulsed stimulator cells (prepared as described above) in the presence of 20 U/ml IL-2 
and 10 ng/ml IL-7. Fresh T-cell medium with cytokines was added every 3-4 days.  
Alternatively, PBMC at the concentration of 2×106 cells/ml were cocultured with 
peptide-pulsed stimulator cells (2×105 autologous DC/well + 1×105 irradiated T2 
cells/well). The cultures were treated as described above, except for purification of 
CD8+ T-cells from the cultures on day 7 using MACS CD8 isolation kit. CD8+ T-cells 
were then readjusted to the concentration of 1×106 cells/ml, rested overnight in T-cell 
medium and further restimulated weekly with peptide-pulsed, preactivated autologous 
DC (2 ×105 DC per well). 
2.2.5 CTL cloning 
Peptide-specific CTL lines were cloned by limiting dilution in 96-well round-bottom 
plates. Each well received 1×104 γ-irradiated (30 Gy) autologous PBMC pulsed with 
corresponding peptide. T cells from previously generated peptide-specific T cell lines 
were added in 200 µl T-cell medium supplemented with 50 U/ml IL-2 and 10 ng/ml 
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IL-7. Three independent dilutions were made containing 10, 3, and 1 responder T cell 
from peptide-specific T-cell lines per well. Every 3-4 days half of the medium was 
removed and substituted with fresh T cell medium containing 50 U/ml IL-2 and 10 
ng/ml IL-7. At days 7 and 14 of culture, T-cells were restimulated with 1×104 
irradiated, peptide-pulsed autologous PBMC. After 3 weeks, wells exhibiting T-cell 
growth were identified under the microscope, and transferred into new 96-well plates 
for testing peptide-specificity and further cultivation. To test peptide-specificity, 
1×104 irradiated (100 Gy) T2 cells pulsed with corresponding peptide were added to 
each well in 150 μl T-cell medium without cytokines. The supernatants were 
harvested 16 hours later and 200 μl fresh T-cell medium with 50 U/ml IL-2 and 10 
ng/ml IL-7 was added to each well. The supernatants were then analyzed for IFN-γ in 
ELISA. The clones were further cultivated for additional 10 days; every 3-4 days half 
of the medium was substituted with fresh T-cell medium with IL-2 and IL-7. After 10 
days, the clones that secreted IFN-γ in the first test were transferred into new plates, 
each divided between two wells. As in the first test, one well per clone was 
restimulated with T2 cells pulsed with the corresponding peptide and the second well 
was restimulated with T2 cells without the peptide as a negative control. The 
supernatants were harvested 16 hours later and tested in IFN-γ ELISA. 
2.2.6 T2 binding assay 
T2 cells were washed three times with PBS and resuspended in serum-free RPMI 
medium at the concentration of 1.5×106 cells/ml. T2 cells were then incubated 
overnight in 50 μl of serum-free RPMI in presence or absence of 50 μg/ml peptide in 
U-bottom 96-well plate at 37°C, 5%CO2. The peptide binding to HLA-A2 was 
assessed by flow cytometry using HLA-A2.1 specific mAB (clone BB7.2) that 
recognizes stabilized HLA-A2.1 complexes. The fluorescence index (FI) was 
calculated from the mean fluorescence intensities (MFI) according to the following 
formula:  
)2(
)2()2(
TMFI
TMFIpeptideTMFIFI −+=  
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2.2.7 Flow cytometry 
For phenotypic analysis, the cells were resuspended in PBS+2% heat-inactivated 
human serum and labeled with primary antibodies. The majority of the primary 
antibodies were directly fluorochrome-labeled except for anti-HLA-A2.1. For anti-
HLA-A2.1, after labeling with the primary antibody the cells were washed 3 times 
with PBS and incubated with the secondary antibody. The antibody labeling was 
performed for 5 minutes at room temperature, except for anti-CCR7 and anti-HLA-
A2.1 antibody (30 minutes at 4°C). Cells were washed three times with PBS buffer 
and either resuspended in PBS and analyzed immediately or fixed in PBS+4% 
formaldehyde. Analysis was performed on a FACScan flow cytometer (Becton 
Dickinson, Heidelberg, Germany) using CellQuest software (Becton Dickinson). 
2.2.8 Phagocytosis assay 
Effector cells were washed twice with PBS and incubated with Saccharomyces 
cerevisiae at a concentration of 106 cells/ml at 37°C in culture medium. After 1 hour, 
cells were washed and stained with Hematoxylin/Eosin. Yeast particles phagocytosed 
to more than 50 % were counted under the inverted microscope (Leica DMIL, Leica 
Mikrosysteme Vertrieb GmbH, Bensheim, Germany) in a total of 100 cells. Percent 
phagocytosis (number of cells containing yeast per 100 cells) and phagocytic index 
(mean number of yeast particles per phagocytic cells) were calculated. 
2.2.9 Migration of dendritic cells 
MoDC matured with the indicated stimuli for 48 hours were harvested, washed and 
tested for migration toward the chemokine CCL21 (6Ckine, a ligand for CCR7) in a 
transwell migration assay. Lower chambers of transwell plates (5.0 µm pore size, 
Costar, Corning, NY) were filled with 350 µl RPMI containing 10% FCS with or 
without CCL21 (40 ng/ml). 1-2×104 DC were added in 50 µl RPMI/10%FCS into the 
upper chamber. After 3-4 hours of incubation (37°C, 5% CO2) the upper chambers 
were removed. Cells in the lower chambers were harvested, and counted using a 
hemocytometer. For each protocol, migration towards CCL21 and towards medium 
without chemokine was performed in duplicate wells. 
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2.2.10 Cytokine ELISA   
Cytokine secretion by stimulated MoDC was measured by ELISA. IFN-γ, IL-6, IL-
12p40, IL-12p70, TNF-α and IL-10 ELISA were performed according to the 
manufacturer's instructions. Briefly, the Maxisorp plates (Nunc, Wiesbaden, 
Germany) were coated with 50 μl/well Catch Antibody solution in Coating Buffer* 
overnight at 4°C. After overnight incubation, the antibody solution was removed and 
the plates were blocked with 300 μl PBS containing 10% FCS for 1 hour. The plates 
were next washed once with PBS containing 0.05% Tween-20 (PBS-T). The 
supernatants (50 μl/well) were incubated on ELISA plates for 2 hours at room 
temperature. The titration of the standard cytokine solution was included in each 
plate. Each condition was performed in duplicate wells. After 2 hours of incubation, 
the plates were washed 5 times with PBS-T and incubated with 50 μl/well detection 
solution (Detection Antibody + Streptavidin-HRP reagent) for additional 1 hour at 
room temperature. The plates were next washed 6 times with PBS containing 0.05% 
Tween-20 and 100 μl substrate solution was added to each well. The HRP-substrate 
was tetramethylbenzidine (TMB) + hydrogen peroxide (BD Pharmingen); the color 
reaction was terminated by adding 50 µL sulphuric acid (2 N) to each well. Plates 
were read in a Sunrise microplate ELISA reader (Tecan, Salzburg, Austria) using 
Magellan software (Tecan).  
* Coating Buffer:   0.1 M Sodium Carbonate, pH 9.5  
2.2.11 The enzyme-linked immunospot (ELISPOT) assay 
ELISPOT assays were performed in 96-well PVDF membrane plates (MultiScreen®, 
Millipore, Schwalbach, Germany). ELISPOT plates were pre-wetted with 80% 
ethanol for 10 minutes. The plates were washed twice with sterile PBS and coated 
overnight at 4°C with 50 μl/well of the capture anti-human IFN-γ mAB solution (20 
μg/ml). After overnight incubation, the antibody solution was removed and the plates 
were washed once with sterile PBS. In order to prevent unspecific protein binding, the 
plates were incubated with RPMI medium supplemented with 10% FCS for 2 hours at 
room temperature. The blocking solution was then removed and the plates were 
washed once with sterile RPMI. CTL were cocultured overnight (37°C, 5%CO2) with 
target peptide-pulsed T2 cells in ELISPOT plates in 200 μl  of Iscove’s MDM 
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supplemented with 10% pooled heat-inactivated human serum at the concentration of 
5×104 CTL and 104 T2 cells per well. Each condition was performed in duplicate 
wells. After overnight incubation, the cell suspension was removed and the wells were 
washed 6 times with 200 μl/well of PBS containing 0.05% Tween-20. The plates were 
further incubated with 100 μl of biotinylated detection anti-human IFN-γ mAB 
solution in PBS containing 10% FCS (the final antibody concentration is 0.5 μg/ml) 
for 2 hours at room temperature. The wells were then washed 6 times with PBS-T and 
100 μl/well of Avidin-HRP solution (25 μg/ml in PBS with 10% FCS) was added for 
1 hour at room temperature. The wells were washed 4 times with 200 μl PBS+0.05% 
Tween-20, then 2 times with PBS. 100 µl of Substrate Solution* was added to each 
well for 5-15min. As soon as the spots developed, the reaction was stopped by 
washing the plates under the tap water. The plates were air dried at room temperature 
in the dark. The spots were enumerated under the stereomicroscope (Nikon SMZ800, 
Nikon GmbH, Düsseldorf, Germany) using Lucia Measurement Version 4.8 software 
(Nikon GmbH). 
* Substrate Solution:  10mg/ml stock solution of 3-amino-9-ethyl-carbazole 
(AEC) in N,N-dimethylformamide was prepared. 333.3 
µl of AEC stock solution was mixed with 10 ml of 
0.1 M Acetate Solution (pH 5.0) and filtered through 
0.45 μm membrane filter. 5 µl of 30% H2O2 were added 
immediately before use. 
2.2.12 Western Blot analysis 
MoDC activated for 2 to 24 hours with the indicated stimuli were harvested, washed, 
resuspended at a density of 5x106 cells/ml in Western Sample Buffer* and snap 
frozen. Prior to analysis, lysates were thawed, heated for 3 minutes to 96°C and 
homogenized with a sonicator. 10 µl extract (corresponding to 5×104 cells) per lane 
was loaded onto 10% SDS–polyacrylamide gel and proteins were separated by 
electrophoresis using the BioRad Minigel system (Bio-Rad Laboratories GmbH, 
Munich, Germany). The proteins were transferred to Hybond-P PVDF membrane 
(Amersham Biosciences Europe GmbH, Freiburg, Germany) by electroblotting for 1 
hour using BioRad Trans-Blot apparatus. The membrane was incubated with Blocking 
Buffer** for 2 hours at room temperature. Primary antibodies were then added in 
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Blocking Buffer + 0.1% Tween 20 for overnight incubation at 4°C or for 2 hours at 
room temperature. After washing 4 times for 5 minutes in Blocking Buffer + 0.1% 
Tween 20, secondary antibodies were applied in Blocking Buffer for 2 hours at room 
temperature. Membranes were washed once with Blocking Buffer + 0.1% Tween for 
15 minutes and additional 3 times for 5 minutes. Membranes were developed with 
ECL Western blot system (Santa Cruz). For quantitative Western blot analysis, the 
ECL-signal was quantified using the Lumi-Imager F1 and the LumiAnalyst Version 
3.1 for Windows Software (Roche Diagnostics GmbH, Germany). 
* Western Sample Buffer:  100 mM Tris-HCl, pH 6.8 
     4% SDS 
     0.2% Bromophenol-Blue 
     20% Glycerol 
     200 mM DTT 
** Blocking Buffer:   PBS + 5% nonfat milk powder 
 
2.2.13 Real-Time RT-PCR quantification 
This assay was performed by Dr. Th. Giese, University clinic, Heidelberg and Dr. M. 
Conzelmann, DKFZ, Heidelberg.  
2 x106  cells were collected in 400µl lysis buffer from the MagnaPure mRNA 
Isolation Kit I (RAS, Mannheim, Germany) supplemented with 1% (w/v) DTT and 
mRNA was isolated with the MagnaPure-LC device using the mRNA-I standard 
protocol. The elution volume was set to 50µl. An aliquot of 8.2 µl RNA was reverse 
transcribed using AMV-RT and oligo- (dT) as primer (First Strand cDNA synthesis 
kit, RAS) according to the manufactures protocol in a thermocycler. After termination 
of the cDNA synthesis, the reaction mix was diluted to a final volume of 500 µl and 
stored at –20˚C until PCR analysis. 
Primer sets specific for the sequences of IL-12p35, IL-12p40, IL-6, IL-10 and TNF-α 
optimized for the LightCycler (RAS) were developed and provided by SEARCH-LC 
GmbH, Heidelberg (www.search-lc.com). The PCR was performed with the 
LightCycler FastStart DNA Sybr GreenI kit (RAS) according to the protocol provided 
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in the kits. To control for specificity of the amplification products, a melting curve 
analysis was performed. Only specific products were observed. The copy number was 
calculated from a standard curve, obtained by plotting known input concentrations of 
four different plasmids at log dilutions to the PCR-cycle number at which the detected 
fluorescence intensity reaches a fixed value. This approach dramatically reduced 
variations due to handling errors over several logarithmic dilution steps.  
To correct for differences  in the content of mRNA, the calculated copy numbers were 
normalizes according to the average expression of two housekeeping genes, 
Cyclophilin B and β-actin. Values were thus given as input adjusted copy number per 
µl of cDNA.  
2.2.14 Statistical analysis 
The Students t-test was performed for significance analysis using Microsoft Excel 
program.  
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3 RESULTS 
3.1 Searching for the new vaccination antigens 
3.1.1 HLA-DP-derived antigens 
In unrelated allogeneic stem cell transplantation, HLA-DP is mismatched between 
donor and recipient in more than 70% of transplanted patients [198]. In the context of 
HLA-DP-mismatched allogeneic SCT, polymorphic antigens derived from different 
HLA-DP alleles represent potential targets for immunotherapy. MHC class II 
expression, including HLA-DP, is restricted mainly to hematopoietic cells and their 
progeny, but the expression was also found on most malignant blood cells. The 
immune reaction against recipient HLA-DP allele variant may therefore eliminate the 
recipients’ hematopoietic system together with the malignant cells. Thus, we 
identified and characterized polymorphic antigens derived from different HLA-DP 
alleles as potential targets for vaccination in context of allogeneic SCT. 
3.1.2 HLA-DP sequence analysis and MHC class I binding epitope prediction 
The sequences for human HLA-DP are available from Immunogenetics database 
(IMGT/HLA, http://www.ebi.ac.uk/imgt/hla/index.html). The database contains 
sequences for all officially recognized HLA alleles [216]. There are more than 20 
alleles for HLA-DPA1 gene and around 430 alleles for HLA-DPB1. We analyzed 
these sequences using two different MHC-binding prediction tools: BIMAS 
(http://bimas.cit.nih.gov/molbio/hla_bind/, [217]) and SYFPEITHI 
(http://www.syfpeithi.de/, [218]). These tools employ two different computational 
algorithms for MHC-binding prediction based on the published information on the 
allele-specific binding motifs. They allow to locate the peptides within the sequence 
containing peptide-binding motifs for HLA class I alleles. This study focused on the 
HLA-A*0201 allele of MHC class I, due to its abundance in the human Caucasian 
population (almost 50% are HLA-A*0201+ [219]). The 9-mer and 10-mer peptides 
derived from polymorphic regions of the HLA-DP molecules with peptide-binding 
motifs for HLA-A*0201 were identified. These peptides are derived from 3 
polymorphic regions within HLA-DPA1 and 8 polymorphic regions within HLA-
DPB1. The results of the prediction analysis are summarized in Table 1. 
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HLA-
DP 
start 
position sequence 
BIMAS 
score 
SYFPEITHI 
score 
HLA-DP alleles expressing the peptide 
variant 
FMFEFDEDEM 122.685 20 *01031, *01032, *0105, *0107, *0203, *0301, *0302 
FMFEFDDDEM 122.685 18 *0104, *0108, *0401 
9 
FMFEFDEDEQ 0.368 13 *0106, *020** 
FDEDEMFYV 8.555 11 *01031, *01032, *0105, *0107, *0203, *0301, *0302 
FDDDEMFYV 53.468 12 *0104, *0108, *0401 
13 
FDEDEQFYV 3.720 11 *0106, *020** 
AILNnNLNTL 24.997 25 All but *03 and *04 
AISNnNLNTL 6.756 27 *03 
AILNNNLNIA 2.384 21 *04 
ILNNNLNTL 83.527 30 All but *03 and *04 
ISNNNLNTL 0.545 20 *03 
HLA-
DPA1 
51/52 
ILNNNLNIA 7.964 22 *04 
QQGDVYICQV 66.498 15 *01011 164 
QQGDVYTCQV 28.912 11 *02012, *04 
YELDEAVTL 28.986 19 
*010**, *030**, *0501-1401, *1601, *1701, *1901-
2201,*25-27, *29-31, *35-38, *44, *45, *50, *52, *54-
58, *63, *65, *67-70, *76, *78-79, *84-85, *87-91 
YELGGPMTL 7.070 20 *02, *04, *23,*24, *31, *32, *39, *41, *46-49, *51, *59-60, *66, *71-73, *75, *77, *80-83, *86 
81 
YELVGPMTL 7.070 18 *15, *18, *28, *34, *40, *53, *62, *74 
YIYNREEYA 27.099 15 All but… 
YIYNREEFV 379.384 21 
*0201*, *0301*, *0402, *06-10, *14, *16-20, *23, 
*25, *29, *30, *32, *35, *37, *41, *45-47, *50, *52, 
*54, *55, *57, *59-61, *67-71, *73, *75, *77-80, *82-
84, *86-88, *9101 
YIYNREELV 68.979 21 *0202, *0501, *21-22, *34, *36, *38, *44, *48, *58, *62-63 
HLA-
DPB1 
28 
YIYNRQEYA 27.099 15 *7401 
Table 1  Identification of peptides derived from the polymorphic regions of 
the HLA-DR molecules. The protein sequences of all known HLA-DPA1 and HLA-
DPB1 alleles were analyzed using BIMAS and SYFPEITHI MHC-binding prediction 
tools. The peptides derived from polymorphic regions of the HLA-DP molecules with 
peptide-binding motifs for HLA-A*0201 were identified. Highlighted in yellow are 
20 peptides with the best prediction scores that were synthesized for further analysis. 
The polymorphic amino residues are shown in bold.
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HLA-
DP 
start 
position sequence 
BIMAS 
score 
SYFPEITHI 
score 
HLA-DP alleles expressing the peptide 
variant 
YIYNREEFA 27.099 15 *0401, *2401, *2801, *3301, *5101, *5601, *6601, *7201, *7601, *8101, *9001 
ELVRFDSDV 19.822 18 *0202, *0501, *21-22, *34, *36, *38, *44, *48, *58, *62-63 
33/34 
QEYARFDSDV 16.445 11 *11, *15, *74 
DILEEKRAV 
DILEEERAV 
DILEEERAD 
DFLEEERAV 
DFLEEKRAV 
DNLEEKRAV 
0.100 14 
*03, *06, *11, *14-15, *20, *25, *28-29, *44-45, *50, 
*52, *56-57, *59, *61, *67, *69-70, *72-74, *76, *87, 
*91 
DLLEEKRAV 
DLLEERRAV 
DLLEEERAV 
15.827 24 *31, *34 
64 
DLLEEKRAL 4.861 24 
*02, *04, *05, *06, *11, *15, *16, *17, *18, *20, *21, 
*22, *23, *24, *27, *28, *,46, *47, *48, *49, *51, *53, 
*55, *58, *59, *60, *62, *63, *66, *69, *71, *72, *74, 
*77, *80, *81, *82, *83, *85, *86 
RMCRHNYEL 15.428 21 
*01, *08, *09, *10, *14,  *25, *26, *29, *35, *37, *44, 
*45, *50, *54, *56, *57, *65, *67, *68, *70, *73, *75, 
*76, *78, *79, *84 
75 
RVCRHNYEL 1.900 17 
*01, *15, *18, *50, *03, *06, *11, *13, *20, *21, *25, 
*26, *27, *29, *36, *37, *44, *52, 
 *56, *61, *69, *74, *78, *79, *85 
YVYQGRQEC, 
YVYQLRQEC 6.399 11 
*02, *04, *05, *16, *19, *22, *23, *24, *28, *31, *32, 
*33, *34, *39, *40, *41, *46, *47, *48, *49, *51, *53, 
*59, *60, *62, *63, *65, *68, *71, *72, *73, *77, *80, 
*81, *82, *83, *84 
YLFQGRQEC 84.555 17 *03, *06, *11, *13, *20, *21, *25, *26, *27, *29, * 36, *37, *44, *52, *56, *61, *69, *74, *78, *79, *85 
YVHQLRQEC 2.000 10 *09, *10, *14, *17, *30, *35, *45, *54, *55, *58, *66, *67, *76, *86 
7 
YVDQLRQEC 0.800 9 *70 
YQGRQECYA, 
FQGRQECYA 12.744 6 
*01, *02, *04, *05, *08, *15, *16, *18-19, *21-23, 
*27, *31-34, *38-41, *46-51, *53, *57, *59-60, *62-
65, *68, *71-73, *75, *80-84, *89-90 
YQLRQECYA 47.151 8 *03, *06, *11-13, *20-21, *25-27, *29, *36-37, *44, *52, *56, *61,  *69-70, *74, *78-79, *85, *87-88,  
HQLRQECYA 0.349 6 *09-10, *14, *17, *30, *35, *45, *54-55, *58, *66-67, *76, *86, *91 
9 
DQLRQECYA 0.769 5 *70 
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We selected and synthesized 20 peptides derived from the polymorphic regions of the 
HLA-DP molecules with the highest probability of binding to HLA-A*0201 
according to both prediction tools. (Table 1 and 2) 
3.1.3 HLA-A*0201 binding affinity of HLA-DP-derived peptides 
The binding affinity of the peptides to HLA-A2 molecules, as predicted by theoretical 
analysis, was validated by the T2 cell binding assay. T2 is an HLA-A2 positive cell 
line that lacks the transporter associated with antigen presentation (TAP) [220, 221]. 
This results in an impaired ability to transport peptides that are endogenously 
produced from intracellular proteins into the ER. Therefore, only the peptides derived 
from the C-terminus of the transmembrane and soluble proteins of the secretory 
pathway have access to MHC class I molecules in the ER [46]. Most of these peptides 
have low affinity for MHC class I and thus form unstable complexes resulting in low 
surface MHC class I expression levels [42]. Addition of exogenous HLA-A2 binding 
peptides to the TAP deficient T2 cells stabilizes the peptide/MHC complexes and 
increases the expression level of the HLA-A2 on the cell surface. This allows the 
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Figure 1 Binding of HLA-DP-derived peptides to HLA-A2. Relative binding 
affinity of synthetic HLA-DP-derived peptides was assessed in T2 binding assay. Two 
Melan-A derived HLA-A*0201-restricted peptides were used as positive controls: 
intermediate affinity AAGIGILTV peptide and high affinity ELAGIGILTV peptide. Mean 
fluorescence index (FI) values of at least three independent experiments are shown. 
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determination of the relative affinity of peptides to the MHC-I molecule. Two Melan-
A derived HLA-A*0201-restricted peptides that are known to be immunogenic were 
used as positive controls: the naturally occurring AAGIGILTV peptide with 
intermediate affinity for HLA-A2 and its synthetic analog (10-mer peptide 
ELAGIGILTV), modified to bind to HLA-A*0201 with higher affinity. Among the 20 
synthetic HLA-DP-derived peptides, 14 peptides showed intermediate affinity binding 
(comparable with intermediate affinity peptide AAGIGILTV or higher), 5 peptides 
showed low affinity binding and 1 did not show any detectable binding to HLA-
A*0201 (Figure 1 and Table 2). These results demonstrate the reliability of the 
theoretical prediction of MHC class I peptide binding by BIMAS and SYFPEITHI 
tools. 
3.1.4 In vitro generation of antigen-specific CTL lines: immunogenicity and 
cross-reactivity of HLA-DP-derived peptides 
In order to investigate whether HLA-DP-derived peptides could stimulate CD8+ 
responses, we next attempted to generate CD8+ T-cell lines against HLA-DP-derived 
peptides from PBMC of healthy HLA-A2 positive donors. CD8+ cells were separated 
from PBMC and were then activated with irradiated TAP-deficient T2 cells pulsed 
with synthetic peptides. The Melan-A-derived peptide ELAGIGILTV, which is 
known to be highly immunogenic [52], was used as a positive control. CTL cultures 
were further restimulated every week with peptide-pulsed, irradiated T2 cells. 
We checked the peptide specificity of the CTL-lines by means of IFN-γ production in 
response to peptide-pulsed T2 cells in ELISPOT assays and/or ELISAs starting from 
week 4 of culture. Specific T-cell responses were observed against 9 out of 12 tested 
peptides (#4007-#4011, #4013-#4015, #4016, Figure 2). 
Peptides #4007-#4011 and #4013-#4015 represent two groups of polymorphic 
peptides. Peptides #4007-#4011 differ in positions P6, P8 and P9 and peptides #4013-
#4014 in positions P2, P4 and P9. P2, P8 and P9 are known to be anchor positions for 
HLA-A*0201 and influence the binding affinity of the peptide to MHC molecules 
(see Chapter 1.2.2.2). However, different amino acids in P6 and P4 theoretically could 
alter the recognition of MHC-bound peptide by the TCR. To verify this possibility we 
checked whether the CTL-lines generated against one of the peptide cross-recognized 
all other polymorphic variants within one polymorphic group with the same 
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efficiency. As shown in Figure 3, CTL cultures generated against the peptide #4013, 
#4014 and #4015 recognized all peptides within the polymorphic group with equal 
efficiency, and the same was true for the second polymorphic group of peptides 
(#4007-4011). These results show that the polymorphic synthetic peptides within each 
group are cross-reactive. 
For the aim of vaccination against the recipients’ HLA-DP allele after HLA-DP 
mismatched allogenic SCT, it is essential that the CTL against recipients’ HLA-DP do 
not recognize the donor HLA-DP variant. Differential recognition of polymorphic 
peptides could result from 1) differential recognition of polymorphic peptides by CTL 
or 2) different natural processing of various HLA-DP variants and natural presentation 
of HLA-DP-derived peptides on MHC class I molecules. As shown in Figure 3, the 
polymorphic peptides were cross-recognized by CTL cultures generated against the 
other peptides within the group. We therefore next investigated whether the 
polymorphic peptides are differentially processed and presented.  
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Figure 2 Immunogenicity of HLA-DP-derived peptides. CD8+ T-cell lines against 
twelve HLA-DP-derived peptides (#4000, #4007-4011, #4013-4018) and Melan-A 
derived ELA peptide were generated from PBMC of healthy HLA-A2 positive donors. 
CD8+ cells were purified from PBMC and were weekly stimulated with irradiated peptide-
pulsed T2 cells. Peptide-specificity of CTL cultures was assessed by IFN-γ release in 
response to peptide-pulsed target cells in ELISPOT assay. T2 cells pulsed with the 
corresponding peptide or with an unrelated peptide (negative control) were used as targets. 
The results of the ELISPOT assay of 4 week old CTL cultures from one out of 6 donors 
are shown. Results are mean values from an experiment done in duplicates. 
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The main sources of MHC class I-binding antigenic peptides are cellular proteins 
which are degraded as part of the normal protein turnover (see Chapter 1.2.2.2). This 
degradation involves the ubiquitin-proteasome system as well as several downstream 
aminopeptidases. The protein degradation system though enabling generation of a 
broad pool of MHC class I epitopes, still has a certain specificity for the sequence of 
the substrate which is not yet totally understood. Not all the peptides theoretically 
predicted to bind MHC class I will be produced naturally by the cell’s proteolytic 
system. We therefore investigated, whether the HLA-DP-derived peptides used in this 
study are naturally presented. This could be checked using allogeneic HLA-A*0201+ 
B cells or EBV-transformed B cell lines, expressing various HLA-DP-alleles. We 
generated B-cell lines from different donors typed for HLA-DP alleles. These B-cell 
lines were allogeneic, therefore, recognition of these cell lines by CTL cultures could 
involve antigens different from the HLA-DP alleles relevant for this study. Thus, 
allogeneic activity of CTL cultures had to be excluded in order to determine the 
specific CTL recognition of the HLA-DP-derived peptide variant. To avoid non-HLA-
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Figure 3 Cross-reactivity 
of HLA-DP-derived peptides 
within the polymorphic 
peptide group. 
CTL-lines generated against the 
peptides (A) #4013, #4014, 
#4015 and (B) #4007, #4009, 
#4011 belonging to two 
polymorphic groups of HLA-
DP-derived peptides (#4007-
4011 and #4013-4015) cross-
recognized all other polymorphic 
variants within the group with 
the same efficiency. The results 
of one representative IFN-γ 
ELISA are presented. T2 cells 
pulsed with every peptide within 
the polymorphic group or with 
an unrelated peptide (control) 
were used as target cells. Results 
are normalized to the IFN-γ 
amount secreted by CTL-
cultures in response to T2 cells 
pulsed with the specific peptide. 
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DP-related allogeneic recognition of target cells, peptide-specific CTL had to be 
cloned. 
In order to obtain monoclonal CTL, peptide-specific CTL cultures were further cloned 
in 96-well plates using peptide-pulsed, irradiated autologous PBMC as stimulator 
cells. After 3 weeks, the generated T-cell clones were checked for peptide specificity 
by measuring IFN-γ in ELISA assays, using peptide-pulsed T2 cells as targets. 
However, no peptide-specific clones could be detected (124 clones tested, data not 
shown). Most of the tested clones recognized T2 cells which were not pulsed with any 
peptide, suggesting that the T2 cells, which were used to restimulate the CTL-cultures 
induced nonspecific responses themselves. Thus, the protocol of peptide-specific CTL 
lines generation had to be optimized to reduce nonspecific CTL responses against T2-
cells. 
3.1.5 Optimization of the in vitro generation of peptide-specific CTL cultures 
from PBMC of healthy donors 
a) Using autologous DC as APC 
As peptide-pulsed T2-cells primed a strong non-peptide-specific CTL response, we 
next attempted to generate peptide-specific T-cell-lines using autologous DC as APC. 
It was previously published by Kaiser and colleagues [222] that DC most efficiently 
induced specific CD8+ responses when used in maturing state, 6 hours after 
activation. Therefore, DC were activated for 6 hours with low concentration of E.coli 
or a mixture of GM-CSF, IFN-α, TNF-α and PGE2 to induce maturation. Following 
these stimuli, DC were pulsed with the peptides and co-cultured with CD8+ T-cells. 
The CTL cultures were further restimulated weekly with similarly prepared 
autologous DC. This method allowed the generation of highly-specific CTL-lines 
against the control ELAGIGILTV peptide. However, although stimulation with 
autologous DC reduced unspecific reactivity against T2 cells, this method failed to 
induce any HLA-DP-derived peptide-specific CD8 response (n=5, 8 out of 20 HLA-
DP-derived peptides were tested, data not shown). This suggests that the reduction of 
nonspecific reactivity of CTL cultures stimulated with autologous DC coincided with 
a loss of peptide-specific reactivity. 
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b) Using autologous DC and T2 as APC 
The efficiency of naïve T-cell activation and expansion in response to MHC-
associated antigens depends on the strength and persistence of the signal, delivered by 
the antigen-presenting cell. Variables modifying T-cell response induction involve 1) 
the affinity between the TCR and the MHC–peptide complex, 2) the stability of the 
MHC-peptide complex itself and 3) the co-receptors and co-stimulatory molecules 
associated with T-cell activation [223]. Thus, high affinity peptides provide stronger 
stimuli and may not need additional costimulation, whereas low-affinity peptides 
require additional help to be able to induce effective T-cell responses. 
In contrast to TAP-deficient T2 cells, dendritic cells present a large variety of 
internally processed peptides. Due to the competition of peptides for the binding to 
MHC class I in the ER, most of the peptides presented on the surface of TAP-
competent cells will have a high affinity to the specific MHC allele [224]. Therefore, 
exogenous low-affinity peptides may have a limited chance of being presented on 
MHC class I for an extended period of time [224, 225]. TAP-deficient T2 cells can 
provide prolonged presentation of low-affinity peptides, required for efficient 
activation of naïve T-cells, but they lack costimulatory molecules, such as CD80 and 
CD86. In contrast, dendritic cells express high levels of CD80/CD86, but may rapidly 
loose peptide expression. Comparing two control peptides ELAGIGILTV (high 
affinity) and AAGIGILTV (intermediate affinity), we investigated whether the 
combination of autologous DC and T2 cells is able to induce stronger specific CD8+ 
T-cell responses against moderate-affinity peptides than DC alone. 
Therefore, the protocol for priming peptide-specific CTL-responses was changed. 
Unsorted PBMC were activated on day 0 with peptide-pulsed, preactivated, 
autologous DC either alone or in combination with T2 cells. After one week, CD8+ 
cells were purified from these cultures in order to remove persisting T2 cell and to 
avoid non-specific CTL-responses. Cultures were further restimulated every week 
with peptide-pulsed, preactivated, autologous DC. Peptide-specific reactivity was 
determined in IFN-γ ELISPOT assays starting from week 4. As shown in Figure 4, 
both, DC alone and DC in combination with T2 cells induced similar responses 
against high affinity ELAGIGILTV peptide. In contrast, CTL-responses against 
intermediate affinity AAGIGILTV peptide were significantly stronger induced when 
primed with DC in combination with T2 cells. As most of the synthetic peptides had 
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an intermediate affinity to HLA-A2 similar to the AAGIGILTV peptide, this latter 
method was further applied for the generation of peptide-specific CTL-lines. 
3.1.6 Generation of CTL lines against HLA-DP derived peptides with an 
optimized method 
HLA-DP-derived peptide-specific CTL cultures were generated from PBMC of 6 
healthy donors using the optimized protocol as described above. CTL-lines were 
stimulated either with the single peptide or with a mixture of peptides. CTL-cultures 
from 1 out of 6 donors responded weakly against the peptides #4007-#4010, #4013-
#4015 and #4017-#4018 after 4 weeks of restimulations (Figure 5). These cultures 
were further restimulated for additional 2 weeks with DC pulsed with the individual 
peptides and then cloned. However, no peptide-specific clones could be detected (254 
clones were checked, data not shown). 
Thus, although some of the HLA-DP-derived peptides were immunogenic (results 
summarized in Table2), it was not possible to generate peptide-specific clones in our 
experimental conditions. The final characterization of the natural presentation of the 
HLA-DP-derived peptides was therefore not possible. This failure to induce peptide-
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Figure 4 Optimization of the method of in vitro generation of peptide-specific 
CTL cultures. CTL lines were generated against high affinity peptide ELAGIGILTV 
(ELA) and intermediate affinity AAGIGILTV (AAG) by priming peptide-specific 
response with peptide-pulsed autologous DC either alone or in combination with 
irradiated T2 cells. The number of the cells producing IFN-γ in response to peptide-pulsed 
T2 cells in week 4 CTL cultures was assessed in IFN-γ ELISPOT assay. Results are the 
mean values + Stdev from the experiments done in duplicates with CTL cultures 
generated in 2 independent experiments from PBMC of 6 different healthy donors. 
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specific CTL-clones may reflect low frequencies of T-cells recognizing HLA-DP-
derived peptides in PBMC of normal donors.  
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Figure 5 Immunogenicity of HLA-DP-derived peptides. CD8+ T-cell lines against 
HLA-DP-derived peptides and Melan-A derived ELA peptide were generated from 
PBMC of healthy HLA-A2 positive donors with an optimized protocol. IFN-γ release by 
CTL cultures in response to peptide-pulsed T2 cells was measured in ELISA. Shown are 
the results of IFN-γ release by CTL generated against 3 peptide mixtures (#4007-4010, 
#4013-4015 and #4017-4018) from one out of 6 healthy donors. 
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Table 2 Immunological characteristics of the HLA-DP-derived synthetic 
peptides: HLA-A2 binding, immunogenicity and crossreactivity. HLA-DP-derived 
synthetic peptides were analyzed for HLA-A2 binding in T2 binding assay. Relative 
HLA-A2 binding is shown as mean fluorescence index (FI) ± standard deviation 
(Stdev) of three independent experiments. Immunogenicity is given as a number of 
positive CTL cultures/number of different donors tested. The ability of CTL-lines 
generated against one of the peptide to cross-recognize other polymorphic variants 
within one polymorphic group was tested (n.d. = not done). 
Peptide 
name sequence 
BIMAS 
score 
SYFPEITHI 
score 
HLA-A2 
binding 
(FI±STDIV) 
Immuno-
genicity 
Cross-
reactivity 
#3999 FMFEFDEDEM 122.685 20 0.4±0.086 0/8 
#4000 FMFEFDDDEM 122.685 18 0.54±0.138 0/10 
n.d 
#4001 FDDDEMFYV 53.468 12 0.22±0.155 0/8 n.d 
#4002 AILNNNLNTL 24.997 25 0.43±0.341 0/7  
#4003 ILNNNLNTL 83.527 30 0.4±0.4 0/7 
n.d 
#4004 QQGDVYICQV 66.498 15 0.24±0.449 0/6 n.d 
#4005 YELDEAVTL 28.986 19 0.16±0.145 0/9 
#4006 YELGGPMTL 7.070 20 0.13±0.196 0/9 
n.d 
#4007 YIYNREEYA 27.099 15 0.31±0.039 3/12 
#4008 YIYNREEFV 379.384 21 0.75±0.25 3/15 
#4009 YIYNREELV 68.979 21 0.59±0.526 3/14 
#4010 YIYNRQEYA 27.099 15 0.61±0.299 3/14 
#4011 YIYNREEFA 27.099 15 0.34±0.241 2/11 
Cross-
reactive 
#4012 ELVRFDSDV 19.822 18 -0.02±0.049 0/6 n.d 
#4013 DLLEEKRAV 15.827 24 0.19±0.22 4/14 
#4014 DLLEERRAV 15.827 24 0.33±0.235 4/14 
#4015 DLLEEERAV 15.827 24 0.36±0.263 4/15 
Cross-
reactive 
#4016 RMCRHNYEL 15.428 21 0.4±0.191 1/9 n.d 
#4017 YLFQGRQEC 84.555 17 0.74±0.12 2/12 
#4018 YQLRQECYA 47.151 8 0.61±0.197 2/12 
n.d 
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3.1.7 IgA and IgD constant region-derived antigens 
Hematological malignancies of B-cell origin usually express one or several 
immunoglobulin isotypes. Antigens, derived from immunoglobulin constant regions 
represent potential candidates for vaccination against B-cell malignancies. This part of 
the study focuses on IgA and IgD isotypes. IgA and IgD are expressed on a subset of 
non-Hodgkin lymphomas and multiple myelomas. We identified MHC class I 
antigens, derived from IgA and IgD constant regions and characterized them as 
potential candidates for a vaccination therapy against B-cell malignancies after SCT. 
3.1.8 IgA and IgD derived peptides 
Similar to the analysis of HLA-DP alleles, the sequences of the IgD and IgA constant 
regions were screened for the occurrence of specific peptides containing HLA-
A*0201 peptide-binding motifs with BIMAS and SYFPEITHI prediction tools. The 6 
top-scored peptides for each isotype were synthesized and taken into further analysis 
(Table 3). These peptide sequences were specific for IgA or IgD isotypes, and were 
not present in any other Ig isotype (in the IgG isotypes or the IgE or in the IgD/IgA 
respectively). 
Peptide 
name Isotype 
Start 
position sequence 
BIMAS 
score SYFPEITHI score 
#4844 IgA 137 LLLGSEANL 134.369 28 
#4845 IgA 331 RLAGKPTHV 69.552 25 
#4846 IgA 239 ELALNELVTL 4.0 27 
#4847 IgA 144 NLTCTLTGL 49.134 24 
#4848 IgA 232 LLPPPSEEL 17.795 27 
#4849 IgA 128 SLHRPALEDL 24.075 26 
#4850 IgD 239 SLWNAGTSV 577.282 25 
#4851 IgD 235 TLPRSLWNA 85.698 18 
#4852 IgD 171 YLLTPAVQDL 836.253 28 
#4853 IgD 306 LMWLEDQREV 141.755 23 
Table 3 Identification of peptides derived from the constant regions of the 
IgA and IgD molecules. The protein sequences of IgA and IgD constant regions were 
analyzed for the HLA-A2 binding motifs using BIMAS and SYFPEITHI MHC-
binding prediction tools. The peptides with the best prediction scores that were 
synthesized for further analysis are listed.
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Peptide 
name Isotype 
Start 
position sequence 
BIMAS 
score SYFPEITHI score 
#4854 IgD 365 LLNASRSLEV 118.238 26 
#4855 IgD 255 SLPPQRLMAL 49.134 29 
3.1.9 CTL lines and cloning 
To assess the immunogenicity of the IgA and IgD-derived peptides, peptide-specific 
CTL-lines were generated using an optimized CTL-generation protocol. The cultures 
were first stimulated with the mixture of 3 peptides for 4 weeks and then checked in 
IFN-γ ELISAs for the specific responses against each individual peptide. Positive 
cultures were then further restimulated for additional two weeks with the individual 
peptide. As shown in Figure 6A, only a weak specific response against a number of 
peptides could be detected after 4 weeks of restimulations. After additional 2 weeks of 
restimulation with individual peptides, positive CTL cultures against IgD-derived 
peptide #4854 could be generated in 4 out of 10 donors tested (Figure 6B).  
The best responder culture was then used for cloning. Out of 22 clones generated, 21 
recognized specifically peptide #4854 (Figure 6C). 
3.1.10 Natural presentation of the LLNASRSLEV (#4854) epitope 
As the IgD-derived peptide #4854 was capable of inducing CD8+ response, natural 
presentation of this epitope had next to be determined. 
In order to investigate if the MHC class I antigen processing pathway is capable of 
generating the LLNASRSLEV peptide (#4854) from the IgD protein, we checked 
peptide-specific CTL cultures and clones for their ability to recognize normal and 
malignant IgD-expressing cells. 
IgD is expressed in healthy individuals on a subset of B-cells. B-cell lines were 
generated from PBMC of the healthy donors as described in Materials and Methods. 
After 4 weeks these cultures contained 60-80% of CD19+ B-cells and 2-4% of CD19-
CD3- non-B non-T cells. IgD was expressed on 60-70% of the B-cell population. The 
cells were sorted by FACS into CD3-IgD+ and CD3-IgD- B-cells (Figure 7). These 
two populations of B cells were further used as target cells. Peptide #4854-specific 
CTL cultures and CTL-clones were used as effector cells in order to assess if the 
LLNASRSLEV epitope is naturally presented. 
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It has been reported that IFN-γ changes the MHC class I peptide presentation profile 
[35-37]. IFN-γ promotes formation of immunoproteasomes that have altered cleavage 
site preferences as well as different cleavage rate as compared to conventional 
proteasomes [33, 34]. Thus, a proportion of IgD+ B-cells was exposed to IFN-γ 
overnight before being used as target cells in order to include the possibility that 
peptide #4854 is better presented under this condition. 
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Figure 6 IgD and IgA derived peptides immunogenicity and CTL clones. CTL 
cultures were stimulated with the mixture of 3 peptides. After 4 weeks IFN-γ release in 
response to T2 cells pulsed with individual peptides and unrelated peptide as a negative 
control was tested in ELISA. (A) The IFN-γ ELISA results for week 4 CTL cultures of one 
out of 10 donors are shown. Positive cultures were further restimulated for additional two 
weeks with autologous DC pulsed with the individual peptide. (B) The best responder CTL 
culture against IgD-derived peptide #4854 after 6 week of culturing is shown. This culture 
was then used for cloning. (C) The peptide-specificity of CTL clones was screened by IFN-γ 
release in response to peptide-pulsed T2 cells. The representative ELISA results are shown.
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As shown in Figure 7B, peptide-specific CTL culture and clones recognized T2 cells 
pulsed with peptide #4854 and moderately recognized IgD- peptide-pulsed B-cells, 
indicating that CTL cultures and clones can recognize the peptide, presented on B-
cells. However, no IFN-γ production could be detected neither by the CTL clones nor 
by the CTL culture in response to IgD+ B cells (Figure 7B). These results suggest that 
LLNASRSLEV epitope is not naturally presented by IgD+ B-cells. 
In order to further confirm that the LLNASRSLEV epitope is not naturally presented, 
we examined if tumor cell lines expressing IgD and HLA-A2 are recognized by 
peptide #4854-specific CTL culture. 
Several multiple myeloma cell lines (KMS-12-BM, LP-1 and IM9) were tested for the 
expression of HLA-A2 allele and IgD protein by flow cytometry analysis. All cell 
lines tested expressed intracellular IgD (Figure 8A). No surface IgD expression could 
be detected. The IgD+ HLA-A2+ IM9 cell line was taken as a target cell line for 
testing peptide #4854 presentation and the IgD+ HLA-A2- LP-1 cell line was used as a 
negative control. 
As shown in Figure 8B, the peptide #4854-specific CTL culture was able to recognize 
only the HLA-A2+ IM9 cell line if exogenously pulsed with peptide #4854, but not 
the IM9 cell line alone. The HLA-A2- LP-1 cell line was not recognized, even if 
pulsed with peptide #4854. These data indicate that although IM9 cell line is capable 
of presenting LLNASRSLEV peptide in context of HLA-A2, this epitope is not 
occurring naturally in malignant cells. 
Taken together, we could not detect naturally presented LLNASRSLEV peptide on 
the surface of normal IgD+ B-cell, nor on a malignant IgD+ multiple myeloma cell 
line. This epitope is therefore not a suitable target for vaccinations. 
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Figure 7 Natural presentation of the LLNASRSLEV (#4854) epitope: 
recognition of IgD+ and IgD- B cells. B-cell lines were generated from PBMC of the 
healthy donors by culturing for 4-6 weeks in presence of CD40L-tranfected BHK cells 
and IL-4. Starting from week 4 the cultures were checked for CD19 and CD3 expression 
by FACS analysis to assess the percentage of B-cells and T-cells in the culture. (A) One 
representative B-cell culture after 4 weeks of cultivation is shown. (B) The cells were then 
sorted by FACS into CD3-IgD+ and CD3-IgD- B-cells. The FACS analysis of the B-cell 
populations before and after the sorting is presented. These two populations of B cells 
were rested overnight and further used as target cells for IgD-derived peptide #4854-
specific CTL cultures and clones to assess the natural presentation of the peptide. Peptide 
#4854-specific CTL culture or CTL clones were coincubated with IgD+ B-cells, IgD+ B-
cells exposed overnight to IFN-γ (IgD+ B-cells + IFN-γ ΟΝ) or IgD- B-cells. T2 cells 
pulsed with peptide #4854 and with an unrelated peptide were used as positive and 
negative controls correspondingly. IgD- B-cells exogenously pulsed with peptide #4854 
were used to control the ability of CTL clones to recognize the peptide presented on B-
cells. Supernatants after 16 hours were checked for IFN-γ production in ELISA (C). 
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Figure 8 Natural presentation of the LLNASRSLEV (#4854) epitope: Recognition 
of IgD+ multiple myeloma cell lines. (A) FACS analysis of IgD and HLA-A2 by LP-1 and 
IM9 multiple myeloma cell lines is shown (IgD and HLA-A2 specific antibodies: open 
histogram, solid line; antibody isotype control: filled histogram, dotted line). (B) CTL 
culture specifically recognizing peptide #4854 was coincubated with IgD+ HLA-A2+ IM9 
cell line alone or pulsed with peptide #4854 and the peptide #4854-pulsed IgD+ HLA-A2- 
LP-1 cell line as a negative control. Supernatants after 16 hours were checked for IFN-γ 
production in ELISA. 
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3.2 The role of GSK-3 in differentiation and activation of pro-
inflammatory DC 
GSK-3 is a multifunctional enzyme critical for cellular differentiation, apoptosis, self 
renewal and motility. More than 40 proteins including 17 transcription factors have 
been reported to be substrates of GSK-3 (reviewed in [226]). Two isoforms of GSK-3 
(GSK-3α and GSK-3β) have been described which are highly homologous in their 
kinase domain, but little is known about isoform-specific functions. GSK-3 is 
regulated by multiple mechanisms including phosphorylation of GSK-3 itself and its 
target proteins, intracellular localization and formation of protein complexes, such as 
β-catenin/GSK-3 in the canonical wnt-pathway [226]. 
Here we investigate whether GSK-3 plays a role in regulating differentiation of DC 
from CD14+ monocytes and DC functions. 
3.2.1 GSK-3 promotes DC differentiation of human monocytes 
Differentiation of human DC from CD14+ monocytes requires 4-7 days of culture in 
GM-CSF and IL-4. Addition of the GSK-3 inhibitors LiCl, SB415286 or SB216763 
on day 0 inhibited the development of DC so that monocytes differentiated toward 
macrophage-like cells (Figure 9). Cell yields in day-5 cultures were lower in the 
presence of GSK-3 inhibitors (62±9% in presence of SB415286 compared with 
cultures in the absence of the inhibitor (100%) (n=6)). In contrast to DC produced in 
cultures without GSK-3 inhibitors, these cells showed an elongated macrophage-like 
morphology and strongly adhered to culture dishes (Figure 9A). They also displayed 
strong phagocytic activity when exposed to Saccharomyces cerevisiae (Figure 9B). 
Following activation with E. coli, they expressed similar levels of MHC class I and II 
as did DC. However they differed in expression of DC-specific and 
monocyte/macrophage specific markers. In contrast to DC they showed no CD83 and 
only low CD80 and CD86 expression but strongly expressed CD14 (Figure 9C). 
Furthermore, upon E. coli activation, these macrophage-like cells secreted similar 
levels TNF-α, and higher levels of IL-6 and IL-10, but significantly lower levels of 
IL-12p40 and no IL-12p70 as compared with conventional MoDC (Figure 9D). These 
data suggest that GSK-3 activity is essential for differentiation of monocytes into 
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MoDC and in its absence monocytes will instead differentiate into macrophage-like 
cells. 
3.2.2 GSK-3 is constitutively active in immature DC and inhibits spontaneous 
maturation 
The effects of GSK-3 inhibitors on immature DC and during activation of DC were 
next investigated. 
GSK-3 is negatively regulated by phosphorylation of an N-terminal serine (Ser-21 for 
GSK-α and Ser-9 for GSK-β). In contrast, GSK-3 activity is facilitated upon 
phosphorylation of Tyr-279 in GSK-α and Tyr-216 in GSK-β [227, 228]. This allows 
monitoring the activity of GSK-3 by comparing the level of Ser-21/9 and Tyr279/216 
phosphorylation. GSK-3 activity can be additionally controlled by the cellular levels 
of GSK-3 substrate β-catenin. Active GSK-3 associates with β-catenin within a 
multiprotein complex. When phosphorylated by GSK-3, β-catenin becomes a target 
for proteasomal degradation [229]. Inactivation of GSK-3 releases β-catenin from the 
complex and thus allows its’ accumulation in the cell. 
Figure 9 GSK-3 inhibits macrophage differentiation of human monocytes. 
CD14+ monocytes were cultured for 5 days in the presence of GM-CSF and IL-4. The 
GSK-3 inhibitors LiCl (10mM), SB415286 (10µM) and SB216763 (10µM) were 
added on day 0. After 5 days of culture, cells were either tested in phagocytosis assay 
or were activated with intact E. coli (1:1000, see Methods) for an additional 36h and 
examined for phenotypic maturation and cytokine secretion. (A) Photomicrographs of 
DC culture on day 5 in the absence (upper panel) or presence (lower panel) of the 
GSK-3 inhibitor (SB415286). One representative of 6 cultures is shown. Similar 
results were observed in the presence of LiCl and SB216763. (B) Phagocytosis of day 
5 cultures with and without GSK-3 inhibitors. Left panel: Phagocytic Index (Number 
of yeast particles per cell), right panel: Proportion of cells containing yeast particles. 
(Mean values ± Stdev, n=4, * p<0.05; ** p<0.01). (C) Flow cytometric analysis of DC 
surface maturation marker expression following activation with E. coli for 36h. One 
representative of 4 experiments is shown. (D) Cytokine secretion of E. coli activated 
cells. Supernatants were harvested 36 hours following activation. Absolute cytokine 
levels of E.coli-activated MoDC (set 1): IL-12p70: 5.4±2.5 ng/ml; IL-12p40: 
22.2±7.9 ng/ml; IL-6: 28.1±20 ng/ml; IL-10: 2.3±2.3 ng/ml; TNF-α: 10.6±9.5 ng/ml; 
(Mean values ± stdev, n=7-10, * p<0.05; ** p<0.01). 
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Figure 9 GSK-3 inhibits macrophage differentiation of human monocytes. 
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Figure 10  GSK-3 is constitutively active 
in and inhibits spontaneous maturation of 
immature DC. Immature MoDC were washed 
on day 5-7 of culture and resuspended in culture 
medium at a concentration of 2-3x105 cells/ml. 
Cells were either continued in GM-CSF and IL-
4 (iDC), or activated with E. coli (1:1000). LiCl 
(10 mM) or SB415286 (10µM) were added 20 
min prior to activation or together with GM-
CSF and IL-4. (A) Western blot analysis of DC 
lysates harvested 2 hours following activation 
and/or addition of LiCl. β-actin was used to 
control for protein loading. One representative 
picture and quantification of 4 experiments is 
shown. The quantification results were 
normalization to the iDC values, set as 1. 
Shown are the normalized means+Stdev of 4 
experiments, * p<0.05; ** p<0.01. (B) One 
representative western blot analysis of DC 
lysates harvested 2 hours following activation 
and/or addition of SB415286 is shown. (C) 
Flow cytometry analysis and IL-6 ELISAs of 
the supernatants were performed 36 hours after 
exposure to LiCl. Mean fluorescence values of 
CD80, CD86, HLA-A,B,C and HLA-DR and 
IL-6 levels in the supernatants are shown for 
DC relative to DC cultured in the absence of 
LiCl (Mean values ± Stdev, n=4 (FACS), n=14 
(IL-6), * p<0.05 as compared to DC not 
exposed to LiCl). (D) Mean fluorescence values 
of CD80, CD83, CD86 and IL-6 levels in the 
supernatants are shown for DC exposed to 
SB415286 relative to DC cultured in the 
absence of inhibitor (Mean values ± Stdev, n=4, 
* p<0.05 as compared to DC not exposed to 
SB415286) 
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GSK-3 is constitutively active in immature DC as shown by high Tyr279/216-
phosphorylation and low Ser9/21-phosphorylation of GSK-3 (Figure 10A). Lithium 
inhibited GSK-3 activity in immature DC as demonstrated by increased 
Ser9/21-phosphorylation, whereas tyrosine phosphorylation was not altered. The 
reduction of GSK-3 activity by lithium was reflected by increased level of GSK-3 
substrate β-catenin (Figure 10A). In contrast, SB415286 did not increase serine 
phosphorylation of GSK-3 but enhanced β-catenin expression (n=4, Figure 10B). 
Inhibition of GSK-3 activity in immature DC resulted in increased expression of DC 
maturation markers CD80, CD83 and CD86, and higher levels of IL-6 secreted within 
24-36 hours (Figure 10C and 10D). Absolute levels of IL-6 secretion without lithium 
were 177±77 pg/ml; in the presence of GSK-3 inhibitors, lithium and SB415286, 
these were increased to 298±131 pg/ml and 384±131 pg/ml correspondingly. The 
increase in IL-6 production was not due to the differences in cell yields, as GSK-3 
inhibitors did not alter viability or cell yields of DC during the 36-48 hours activation 
period (n=5). These results demonstrate that GSK-3 is constitutively active in 
immature MoDC and inhibits their spontaneous maturation. 
3.2.3 GSK-3 is inhibited during DC activation 
GSK-3 is negatively regulated by several upstream pathways, including PI3K/Akt-1 
pathway [226]. It was recently demonstrated that Akt-1 is activated (Ser473-
phosphorylated) during pro-inflammatory stimulation of DC [141]. Akt-1 has been 
shown to phosphorylate GSK-3 at the inhibitory Ser9/21-moiety [230, 231]. 
Consistent with these observations, the Ser473 phosphorylation of -Akt-1 correlates 
with Ser9/21 phosphorylation of GSK-3 (Figure 11A and 11B). E. coli activated DC 
that showed highest levels of phospho-Akt-1 also showed highest levels of phospho-
Ser9/21-GSK-3. PI3K inhibitor, wortmannin inhibited Akt-1 phosphorylation, and 
this resulted in reduced Ser9/21-phosphorylation of GSK-3 (Figure 11 A and 11B). 
Consistent with the observed higher levels of Ser9/21-phosphorylation of GSK-3, the 
level of β-catenin also increased during DC activation (Figure 11C). 
These results suggest a net inhibition of GSK-3 activity following pro-inflammatory 
DC activation. 
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3.2.4 GSK-3 inhibitors reduce pro-inflammatory cytokine secretion by 
monocytes and DC activated with E.coli 
Martin and coworkers have recently demonstrated that GSK-3 inhibitors enhance IL-
10 secretion and inhibit IL-12p40, IL-6 and TNF-α secretion of human monocytes 
[214]. We therefore next compared the effects of GSK-3 inhibitors on cytokine 
production of activated monocytes and activated DC. 
Monocytes stimulated with intact E. coli (Figure 12D) or LPS (n=6, data not shown) 
did not secrete IL-12p70. In contrast, human DC produced high levels of IL-12p70 
(3400±1200 pg/ml),  and  this  was  nearly  completely  blocked  by  lithium  and  by  
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Figure 11 GSK-3 is inhibited 
during DC activation. MoDC were 
prepared as in Figure 10. Cells were 
either continued in GM-CSF and IL-4 
(iDC), or activated with E. coli (1:1) or 
a BHK-CD40L (in ratio of DC to BHK 
cells 20:1) in presence or absence of 
wortmannin (100ng/ml). (A) Ser21/9 
and Tyr279/216 phosphorylation of 
GSK-3 and Ser473 phosphorylation of 
Akt-1 2 hours following activation 
were analysed by Western Blot. p38K 
acts as protein loading control. One 
representative of 4 experiments is 
shown. (B) Strength of Ser9-
phosphorylation of GSK-3β and (C) 
intracellular β-catenin expression was 
assessed by quantitative 
immunoblotting. Means ± Stdev of 4 
experients are shown. 
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Figure 12 GSK-3 is necessary for IL-12p70 secretion of DC and enhances IL-12p40, 
IL-6 and TNF-α, but not IL-10 secretion by monocytes and DC activated with E. coli. 
Monocytes (right panels, D-E) were resuspended in culture medium at a concentration of 
1x106/ml and directly exposed to E. coli in the presence or absence of LiCl (10mM) or 
SB415286 (10µM). MoDC (left panels, A-C) were either continued in GM-CSF and IL-4 (no 
activation), or activated similar to monocytes. Supernatants were harvested after 36 hours. 
Mean values ± SEM, n=8-18 (monocytes) and n=6 (DC), * p<0.05; **p<0.01 as compared to 
activation without a GSK-3 inhibitor. Absolute cytokine levels in the absence of inhibitors 
(set 1) of E. coli-activated MoDC were: IL12p70: 2.1±1 ng/ml; IL12p40: 54.2±10.5 ng/ml; 
IL6: 109.7±25 ng/ml; IL10: 7.2±0.8 ng/ml; TNF-α: 16.1±3.8 ng/ml. Absolute cytokine levels 
of E. coli-activated monocytes (set 1): IL12p70: 0±0 ng/ml; IL12p40: 0.77±0.68 ng/ml; IL6: 
58.2±24.1 ng/ml; IL10: 2.2±0.7 ng/ml; TNF-α: 3.2±1.2 ng/ml. 
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SB415286 (Figure 12A). IL-12p40 secretion was partially inhibited in both, 
monocytes and DC (Figure 12A and D). Furthermore, IL-6 and TNF-α were also 
partially inhibited to similar degrees in monocytes and DC by the two GSK-3 
inhibitors (Figure 12B and E). We could not detect any significant effect of lithium on 
IL-10 secretion by monocytes and DC (Figure 12C and F). IL-10 secretion was 
inhibited to a minor degree by SB415286 in DC only. As GSK-3 inhibitors have been 
reported to enhance IL-10 secretion [214], we confirmed our observations using 
positively and negatively selected CD14+ monocytes activated with LPS and E. coli at 
high (1:1) and low (1:1000) concentrations (see Methods). However, we did not 
observe significantly enhanced IL-10 secretion in the presence of lithium or 
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Figure 13 Influence of LiCl and SB415286 on phenotypic maturation of DC. 
MoDC were activated with E.coli (A) or BHK-CD40L (B and C) in the presence or 
absence of LiCl (10 mM) or SB415286 (10 µM). Flow cytometry analyses were 
performed 36-48 hours after activation. Relative mean fluorescence values of CD80, 
CD83, CD86, MHC class I and class II are shown. Mean values are related to DC 
activated in the absence of inhibitor (mean values ± Stdev, n=4). * p<0.05; **p<0.01 as 
compared to activation without a GSK-3 inhibitor. 
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SB415286 under any of these experimental conditions (n=4-16, data not shown). 
Flow cytometry analysis of DC activated with E.coli in the presence or absence of 
LiCl or SB415286 (Figure 13A) showed that the inhibitors reduced, but did not 
abrogate the expression of the mature antigen-presenting DC phenotype. 
The capacity of lithium and SB415286 to inhibit GSK-3 in activated DC was 
confirmed by Western blot analysis. Addition of lithium enhanced both, β-catenin 
expression and GSK-3 Ser(9/21)-phosphorylation, within 2 hours following activation 
of DC with low concentrations of E. coli (Figure 10A). 
3.2.5 GSK-3 inhibitors reduce pro-inflammatory cytokine secretion of 
CD40L-activated DC 
Activation of DC using a baby hamster kidney (BHK) cell line transfected with 
CD40L mediates a strong pro-inflammatory signal resulting in the secretion of high 
levels of cytokines. Similar to their effects on E. coli activated DC, LiCl, SB415286 
and 1-Azakenpaullone blocked IL-12p70 secretion and reduced IL-12p40, IL-6 and 
TNF-α secretion of CD40L-activated DC (Figure 14A and data not shown). IL-10 
was not significantly influenced (Figure 14A).  
Flow cytometry analyses of DC activated with BHK-CD40L in the presence or 
absence of LiCl or SB415286 showed a reduced up-regulation of CD83, but no 
influence on CD80, CD86, MHC class I and class II (Figure 13B). 
3.2.6 GSK-3 inhibitors specifically inhibit E.coli- induced migration, but not 
CD40L/cAMP-induced migration 
DC activated with BHK-CD40L migrate poorly toward CCR7 ligands [141], whereas 
upon E. coli activation DC acquire significant migratory capacity. Addition of CD40L 
together with Sp-5,6-DCl-cBIMPS (cBIMPS, a membrane-permeable cAMP analogue 
and activator of PKA) induced migratory capacity. 
We next investigated the influence of GSK-3 inhibitors on CD40L- and E. coli-
induced migration. LiCl and SB415286 did not influence migration of MoDC induced 
by CD40L in presence of cAMP or without cAMP (Figure 14B). However, migration 
induced by E. coli was reduced to about 60% by all GSK-3 inhibitors (LiCl and 
SB415286, Figure 14B, and 1-Azakenpaullone, data not shown). This difference 
between CD40L-activated and E. coli activated  DC  was  further  supported  by  flow  
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Figure 14 GSK-3 enhances pro-inflammatory cytokine secretion by CD40L-
activated DC and reduces migration of E. coli activated DC. MoDC were either 
continued in GM-CSF and IL-4 (no activation), or activated with a BHK-CD40L in the 
presence or absence of LiCl (10mM) or SB415286 (10µM). (A) Cytokine levels in culture 
supernatants 36 hours following activation. Shown are Means ± SEM of 6 experiments, 
(*p<0.05, **p<0.01 as compared to activation with the BHK-CD40L). (B) Migration of DC 
activated with BHK-CD40L cells in the presence or absence of cAMP (cAMP-analogon Sp-
5,6-DCl-cBIMPS, 50µM) or with E. coli was tested in transwell assays. Migration toward 
CCL21 (40 nM) relative to BHK-CD40L+cAMP is shown. Number of separate donors: 
BHK-CD40L+cAMP n=6; E. coli n=15, **p<0.01 as compared to activation without 
inhibitor. (C) CCR7 expression was analyzed by FACS 36hours after the activation. Shown 
are mean fluorescence values related to BHK-CD40L+cAMP ± Stdev. n=6). 
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cytometry analysis of CC chemokine receptor 7 (CCR7) surface expression. 
SB415286 significantly reduced CCR7 expression in all protocols of DC activation 
(Figure 14C). However, this reduction was most pronounced for E. coli activated DC. 
Here, surface CCR7 expression in the presence of the inhibitor did not differ from 
expression by immature DC. 
This suggests that depending on the activation stimulus, GSK-3 influences migration 
of MoDC. 
3.2.7 Reverse effects of PI3K and GSK-3 on IL-12 and IL-10 secretion 
As mentioned previously, the PI3K/Akt pathway is activated during pro-inflammatory 
DC stimulation, thus inhibiting GSK-3. It was shown that inhibition of PI3K by 
wortmannin increases IL-12p70 secretion by activated DC [141]. Therefore, we 
investigated whether wortmannin effects on cytokine secretion could be reversed by 
inhibiting GSK-3 activity. 
Lithium has been shown to inhibit GSK-3 both, directly by replacing Mg2+ [232] and 
indirectly by enhancing PI3K/Akt-1 activity that results in increased Ser9/21-
phosphorylation levels of GSK-3 ([233] and Figure 10A). Thus, some effects of 
lithium may be explained by a modulation of PI3K activity. Therefore, we 
investigated interactions of wortmannin and SB415286, a PI3K-independent GSK-3 
inhibitor which does not increase GSK-3 Ser9/21-phosphorylation (Figure 10B). 
Figure 15 demonstrates that the opposing effects of wortmannin and SB415286 were 
significant for IL-12p70. SB415286 inhibited the wortmannin-enhanced IL-12p70 
secretion of MoDC activated with E.coli (Figure 15) and BHK-CD40L (n=4, data not 
shown). SB415286 significantly decreased wortmannin-mediated IL-12p40 secretion 
only when DC were activated with low concentrations of intact E. coli but not with 
high E.coli concentrations or with BHK-CD40L. No effect on wortmannin-enhanced 
secretion of IL-6 and TNF-α could be detected (Figure 15). Similar results were 
obtained using the second GSK-3 inhibitor, 1-Azakenpaullone (n=4, data not shown). 
This suggests that other, indirect effects may explain the activity of GSK-3 inhibitors 
or wortmannin on the secretion of these cytokines. Alternatively, higher levels of 
GSK-3 inhibitors may be required to block the secretion of IL-6 and TNF-α, if GSK-3 
activity is enhanced by wortmannin. Indeed, SB415286 at a concentration of 25 µM 
and 1-Azakenpaullone at a concentration of 5 µM significantly reduced secretion of 
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all cytokines (induced by wortmannin in combination with BHK-CD40L), however, 
viability was also reduced to about 70% (n=4, data not shown) suggesting that these 
concentrations were approaching cell toxic levels. 
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Figure 15  Reverse 
effects of PI3K and 
GSK-3 on IL-12 and IL-
10 secretion. Immature 
MoDC were prepared and 
activated as in Figure 10. 
SB415286 (10µM) and 
wortmannin (WM, 100 
ng/ml) were added 20 
minutes prior to 
activation; E. coli were 
used in two concentrations 
(1:1 and 1:100; see 
Methods). Supernatants 
were harvested 36 hours 
following activation. 
Means ± SEM of 8 
experiments (E.coli 1:1) 
and 4 experiments (E. coli 
1:100) are shown, 
*p<0.05; **p<0.01 
(comparison of WM vs 
WM+SB415286 only). 
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Interestingly, significant opposing effects of wortmannin and SB415286 were 
observed for IL-10 secretion induced by low concentrations of E. coli (Figure 15). 
Here however, wortmannin inhibited and SB415286 enhanced IL-10 secretion, which 
suggests that E. coli- induced IL-10 secretion is partially inhibited by GSK-3. 
Similarly, BHK-CD40L-induced IL-10 secretion was enhanced by the GSK-3 
inhibitors in the presence of wortmannin (n=4, data not shown). 
Our results substantiate that the enhancing effects of wortmannin on IL-12p70 
secretion depend on GSK-3; and that the phosphorylation of the Ser9/21 moiety of 
GSK-3 by Akt-1 inhibits IL-12p70 secretion. Furthermore, this data support 
observations of Martin et al. [214] of GSK-3 being a partial inhibitor of IL-10 
secretion. 
3.2.8 GSK-3 specifically enhances IL-12p35 mRNA levels and inhibits IL-10 
mRNA levels 
Using real-time PCR quantification, we investigated whether GSK-3 regulates 
cytokine secretion at the mRNA level. CD40L-induced IL-12p35 mRNA was 
significantly inhibited by SB415286 (Figure 16) as early as 3 hours following 
activation. In contrast, IL-12p40 mRNA was reduced in MoDC only after 24 hours of 
activation. IL-10 mRNA was enhanced by SB415286 in all three MoDC cultures after 
12 and 24 hours, however, due to the donor to donor variability (1.6 to 3.8 fold 
enhancement), statistical significance was not reached with three experiments. IL-6 
mRNA was inhibited after 3 and 6 hours but enhanced after 12 hours following 
activation. TNF-α mRNA was not significantly changed by the GSK-3 inhibitor 
(Figure 16). 
These results suggest that GSK-3 regulates IL-12p70 secretion on the level of IL-
12p35 mRNA. In contrast, less direct and less consistent effects were observed for the 
other three pro-inflammatory cytokines, supporting the hypothesis that indirect effects 
of GSK-3 may modulate the secretion of IL-6, IL-12p40 and TNF-α.   
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Figure 16  GSK-3 specifically enhances IL-12p35 mRNA levels and inhibits IL-
10 mRNA levels. Real-time PCR quantification of mRNA in MoDC stimulated with 
BHK-CD40L cell line in the presence or absence of the GSK-3 inhibitor SB415286. 
Specificity of the mRNA signal was controlled by adding BHK-CD40L cells to the 
unstimulated MoDC (0 hours) and by analysing the influence of mock-transfected BHK 
cells (no CD40L) (n=1, not shown). Shown are the means ± Stdev of 3 independent 
experiments normalized to the 24 hour mRNA levels without inhibitor. * p<0.05; 
** p<0.01 (comparison with and without SB415286).  
4. Discussion 
 70
4 Discussion 
4.1 Identification of new potential vaccination antigens 
Immunotherapy provides an opportunity to enhance the effects of conventional 
therapy in cancer patients. This approach aims to induce effective immune responses 
against the tumor cells in patients. These responses are directed against tumor-
associated antigens. Identification and characterization of TAA that can be used for 
vaccination in clinics is an important step of anti-tumor vaccine development. 
TAA can be identified by several strategies including: 1) molecular dissection of 
tumor-reactive T cells isolated from patients [234]; 2) elution of peptides naturally 
presented on the MHC of tumor cells [235]; 3) predicting epitopes from a particular 
protein that are likely to bind to common MHC alleles using bioinformatic programs 
[217, 218]. The latter approach was employed for identification of HLA-A2-binding 
antigens in this study. Predicted peptides can be synthesized, confirmed 
experimentally to bind to MHC, and used to generate peptide-specific CTL. This 
approach allows to focus the research only on specific proteins with desirable 
expression profiles. Moreover, synthetic peptides are easy to produce and the induced 
immune responses are relatively easy to monitor. A major disadvantage of this 
approach, however, is that processing and presentation of the predicted peptides on 
the MHC of the tumor cells can not be guaranteed. 
In this work, MHC class I antigens derived from HLA-DP alleles and from 
immunoglobulin A and D constant regions were identified and evaluated as potential 
targets for vaccination of patients with hematological malignancies after stem cell 
transplantation (SCT). 
BIMAS and SYFPEITHI MHC-binding prediction tools were used to identify 
potential HLA-A*0201-binding epitopes derived from polymorphic regions of HLA-
DP alleles and from constant regions of IgA and IgD. This study focused on the HLA-
A*0201 allele of MHC class I, due to its abundance in the human Caucasian 
population [219]. The theoretical prediction of MHC class I peptide binding was 
reliable as the experimentally measured HLA-A2 binding affinity of 14 out of 20 
synthetic HLA-DP-derived peptides was comparable to that of the control 
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intermediate affinity AAGIGILTV peptide or higher; and only 1 HLA-DP-derived 
synthetic peptide did not show any detectable binding to HLA-A2 (Figure 1). 
4.1.1 Induction of CD8+ T-cell responses against intermediate affinity 
peptides 
Generating peptide-specific CD8+ T-cell lines and CTL clones was a prerequisite for 
the immunological characterization of the peptides in this study. The peptides 
analyzed in this study were binding to HLA-A2 with intermediate to low affinity. 
Moreover, similar to most of the tumor associated antigens, they represent non-
mutated self antigens and thus might be tolerated by the immune system. Therefore, 
the optimization of the method of generating specific CTL lines against moderate 
affinity self peptides represented the main challenge. 
The method initially used for generation of CTL lines employed T2 cells pulsed with 
peptides for priming and restimulation of antigen-specific CD8+ T-cells. This cell line 
is deficient for TAP and therefore endogenously produced antigens do not reach the 
ER and are not presented on the cell surface. Due to the lack of competition of 
endogenous antigens for binding to MHC class I, TAP-deficient T2 cells can provide 
prolonged presentation of exogenously delivered low-affinity peptides [224]. This 
method allowed for generating specific CTL lines against HLA-DP-derived antigens. 
However, this method had a major disadvantage. Repetitive stimulation of CTL-
cultures with T2 cells caused expansion of T-cells recognizing T2 cells independent 
of the exogenous antigen they were pulsed with. This T2 cell-directed response 
usually occurred after 4-5 restimulations and “T2-specific” T-cells rapidly overgrown 
peptide-specific responses thus impeding the generation of peptide-specific CTL 
clones. The target antigens of CTL responses against TAP-deficient T2 cells are not 
known, but could be induced by MHC class I associated peptides, entering the ER via 
TAP-independent pathways. The peptides derived from C-terminus of the 
transmembrane- and soluble proteins of the secretory pathway have access to MHC 
class I molecules in ER in the absence of TAP activity [46]. Moreover, it was recently 
reported that such peptides could serve as neoantigens inducing CTL-responses 
against TAP-deficient tumor variants [47]. 
In order to avoid induction of a strong non-peptide-specific CTL response against T2-
cells, we next used autologous DC as APC for generating peptide-specific T-cell-
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lines. DC have the unique capacity to prime T-cell responses due to expression of 
high levels of co-stimulatory molecules and secretion of T-cell activating cytokines. 
However, this method failed to induce any HLA-DP-derived peptide-specific CD8 
response. The failure of DC to stimulate CTL cultures against intermediate and low 
affinity peptides could probably be explained by the inefficiency of presentation of 
these exogenous peptides by DC. As DC are TAP-competent, they present a large 
variety of internally processed peptides that compete for the binding to MHC class I 
in the ER. Most of the peptides presented on the surface of TAP-competent cells will 
have a high affinity to MHC [224]. Therefore, exogenous low-affinity peptides may 
have a limited chance of being presented on MHC class I for an extended period of 
time [224, 225]. 
The efficiency of T-cell responses against any antigen depends on the avidity of the 
interaction between the T-cell and the antigen presenting cell. This includes 1) the 
affinity of antigen binding to the MHC molecule, 2) affinity between the TCR and the 
MHC–peptide complex and 3) the co-receptors and co-stimulatory molecules 
associated with T-cell activation [223]. Whereas high affinity peptides provide 
stronger stimuli due to the increased stability of the MHC–peptide complex, low-
affinity peptides might require additional help to be able to induce effective T-cell 
responses. We assumed that for the induction of efficient CTL responses against 
intermediate affinity peptides the combination of prolonged peptide presentation and 
efficient T-cell co-stimulation was necessary. TAP-deficient T2 cells can provide 
prolonged presentation of low-affinity peptides, required for efficient activation of 
naïve T-cells, but they lack costimulatory molecules. In contrast, dendritic cells 
express high levels of the costimulatory molecules CD80/CD86, but rapidly loose 
peptide expression [224]. If our assumption is true, the combination of autologous DC 
and T2 cells will be able to induce stronger specific CD8+ T-cell responses against 
moderate-affinity peptides than DC alone. 
This hypothesis was tested on the model of two Melan-A derived HLA-A*0201-
restricted peptides of known immunogenicity that have intermediate and high affinity 
of binding to HLA-A*0201. The Melan-A derived AAGIGILTV peptide occurs 
naturally and has an intermediate affinity. Its synthetic analog (10-mer peptide 
ELAGIGILTV) was modified on the anchor positions to bind to HLA-A*0201 with 
higher affinity [52, 53]. The advantage of these model antigens is that the frequency 
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of peptide-specific CTL precursors is similar. Therefore, the efficiency of the CTL 
response induction will depend only on the different affinity of peptide binding to 
MHC. 
CTL were primed by DC either alone or in combination with T2 cells. In order to 
avoid non-specific CTL-responses, T2 cell were removed from these cultures after 7 
days and CTL were restimulated by DC. Consistent with our hypothesis, DC alone 
and DC in combination with T2 cells induced similar responses against the high 
affinity ELAGIGILTV peptide, whereas CTL-responses against the intermediate 
affinity AAGIGILTV peptide were significantly stronger when primed with DC in 
combination with T2 cells. 
These results suggest that the induction of CTL responses against intermediate affinity 
peptides requires prolonged presentation on the cell surface. Such prolonged 
presentation is achieved by TAP-deficient T2 cells and not by TAP-competent DC, as 
priming CTL with DC did not suffice to induce an efficient response. However, non-
specific responses were also induced by T2 cells. Induction of CTL responses with the 
combination of DC and T2 with subsequent removal of T2 cells from the cultures 
allowed generation of peptide-specific CTL responses against intermediate affinity 
peptides and reduced nonspecific reactivity of these cultures. 
4.1.2 Characterization of HLA-DP-derived antigens 
4.1.2.1 Immunogenicity of HLA-DP-derived peptides 
Although it was previously demonstrated that HLA-DP can be a target antigen of 
CD4+ T lymphocytes [199, 200], CD8+ T-cell responses were not reported. We 
selected for this study 20 peptides derived from the polymorphic regions of the HLA-
DP molecules according to their predicted capacity to bind HLA-A*0201. These 
peptides were synthesized and used to generate peptide-specific CTL lines from 
PBMC of healthy HLA-A2+ donors. Here we demonstrate that CD8+ CTL responses 
could be generated against 11 out of 20 HLA-DP-derived synthetic peptides. Peptide-
specific CTL responses were, however, relatively rare. CTL responses against 
different HLA-DP peptides could be detected in 11 to 28% of tested healthy donors 
(Table 2). 
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4.1.2.2 Crossreactivity of HLA-DP-derived peptides 
For the aim of vaccination against the recipients’ HLA-DP allele after HLA-DP 
mismatched allogenic SCT (See Chapter 1.4), it is essential that the CTL against 
recipients’ HLA-DP do not recognize the donor HLA-DP variant. There are two 
possible situations where such differential recognition of polymorphic peptides can 
take place: 1) the polymorphic peptide from the donor HLA-DP allele is presented on 
HLA-A2, but is not recognized by the CTL raised against the recipients’ HLA-DP 
allelic variant or 2) polymorphic peptide from the donor HLA-DP allele is not 
presented on HLA-A2 due to different natural processing or to a loss of affinity to 
HLA-A2. The first possibility was tested for 2 polymorphic HLA-DP derived peptide 
groups (#4007-#4011 and #4013-#4015), for which peptide-specific CTL lines could 
be generated. We demonstrated that the polymorphic synthetic peptides within each 
group were cross-reactive. The next step in the characterization of polymorphic HLA-
DP-derived peptides was testing their natural presentation. 
4.1.2.3 Cloning of HLA-DP-derived peptides 
As mentioned before, candidate epitopes that are theoretically predicted to bind to 
MHC (even if the MHC binding is conferred experimentally for synthetic peptides) 
will not necessarily be processed and presented on the MHC molecule on the cell 
surface. During processing of the full-length protein, the proteasome may generate 
peptides that are too short to fit in the groove of MHC, or it may cleave the protein at 
sites within the epitope. Sequence and size-preferences for peptide transfer into the 
ER by TAP can additionally contribute to restrictions of the cellular antigen repertoire 
[40, 41]. 
The natural presentation of HLA-DP-derived peptides could be tested using HLA-
A*0201+ antigen presenting cells (e.g. B-cells or DC) expressing different HLA-DP 
alleles. However, potential allogeneic activity of peptide-specific CTL cultures had to 
be excluded in order to determine the specific CTL recognition of the HLA-DP-
derived peptide variant. Therefore, in order to address the question of the natural 
presentation of HLA-DP-derived peptides, the generation of peptide-specific CTL 
clones was required. However, despite using our method of CTL response induction 
which was optimized for the model intermediate affinity AAGIGILTV peptide, CTL 
clones specific for HLA-DP-derived peptide could not be obtained in this study. The 
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possible difference between the Melan-A derived AAGIGILTV peptide and the HLA-
DP-derived peptides used in this study is the frequency of the peptide-specific CTL 
precursors. It was previously shown that T cells specific for the AAGIGILTV have an 
exceptionally high precursor frequency in HLA-A*0201+ individuals [236, 237]. It is 
the only self-antigen for which specific naïve T-cells could be directly detected in 
humans [236]. Therefore, the low frequency of the CTL precursors recognizing HLA-
DP-derived peptides could explain why CTL clones specific for HLA-DP-derived 
peptides could not be generated. 
4.1.2.4 Are HLA-DP derived antigens involved in GvHD development? 
As mentioned in Chapter 1.4, patients mismatched for two HLA-DP alleles have a 
significantly increased risk of GvHD [198], suggesting that immune responses against 
HLA-DP could be involved in GvHD development. This study demonstrated that 
CD8+ CTL responses could be generated against several HLA-DP-derived synthetic 
peptides. The characterization of the natural presentation of the HLA-DP-derived 
peptides, however, was not possible due to an inability to generate CTL clones 
specific for HLA-DP-derived peptides. It would therefore be important to investigate 
whether CTL recognizing these peptides have any impact on GvHD development in 
patients after HLA-DP mismatched allogeneic SCT. This can be tested by monitoring 
CTL responses against HLA-DP derived peptides ex vivo in patients who developed 
GvHD after allogeneic SCT. For this purpose, HLA-A*0201+ donor-recipient pairs 
have to be identified that show particular mismatches in HLA-DP alleles. At the onset 
of GvHD, before steroid treatment is initiated (depleting CTL), T-lymphocytes have 
to be obtained and tested against antigens derived from recipients HLA-DP allele. 
These experiments are planned for the future. 
4.1.3 Characterization of the antigens derived from immunoglobulin A and D 
constant regions 
Antigens derived from immunoglobulin constant regions represent potential 
candidates for vaccination against B-cell malignancies. The potential advantage of 
vaccinating against immunoglobulin constant regions (isotypes) as compared to 
idiotypes (variable regions of Ig) is that isotypes are not unique for the individual B-
cell malignancy but are shared by many patients. This study characterized antigens 
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derived from IgA and IgD isotypes, which are expressed on a subset of non-Hodgkins 
lymphomas and multiple myelomas. 
4.1.3.1 Immunogenicity of IgD- derived LLNASRSLEV epitope 
For this study we selected 6 peptides for each isotype (IgA and IgD) that were 
predicted to bind to HLA-A*0201 (Table 3.). These peptide sequences were specific 
for IgA or IgD isotypes, and were not present in any of the IgG isotypes, the IgE or 
the IgD/IgA respectively. IgA- and IgD- derived peptides were used to generate 
peptide-specific CTL lines and clones. We demonstrated that positive CTL responses 
against the IgD-derived LLNASRSLEV peptide could be induced in 40% of healthy 
HLA-A2+ donors. This epitope could therefore be a promising target for 
immunotherapy against B-cell malignancies. Therefore, CTL clones specifically 
recognizing LLNASRSLEV epitope were generated for further characterization of the 
natural presentation of this peptide. 
4.1.3.2 Immunogenic IgD- derived LLNASRSLEV epitope is not naturally presented 
on the cell surface 
IgD is expressed on a subset of B-cells in healthy individuals and on some B-cell 
malignancies, e.g. multiple myeloma. If the IgD-derived LLNASRSLEV epitope is 
produced following proteasomal degradation of IgD, it can be transported into the ER 
and presented within the MHC class I complex. Therefore, the natural presentation of 
LLNASRSLEV epitope was examined by testing the ability of peptide-specific CTL 
to recognize IgD+ B-cells and IgD+ multiple myeloma cells. However, such a 
recognition could not be detected. This failure was not due to inefficient presentation 
of MHC-class I antigens by the target cells, as the same cells were recognized by CTL 
when pulsed with LLNASRSLEV peptide exogenously. 
It has been reported that IFN-γ changes the MHC class I peptide presentation profile 
[35-37] via formation of immunoproteasomes. However, the LLNASRSLEV-specific 
CTL failed to recognize IgD+ B-cells even preactivated with IFN-γ.  
The data presented in this work demonstrate that IgD-derived LLNASRSLEV-epitope 
was not efficiently processed and presented on HLA-A2 on the surface of either 
normal or malignant cells. Therefore, although CTL responses against this epitope can 
4. Discussion 
 77
be efficiently induced using a synthetic peptide, it will not be presented on the surface 
of tumor cells. 
This epitope was therefore not considered to be a suitable target for vaccinations. 
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4.2 GSK-3 regulates DC differentiation and pro-inflammatory DC 
function 
DC are attractive candidates for active vaccination strategies due to their unique 
capacity to stimulate both humoral and cell-mediated immune responses. DC undergo 
a complex developmental program through three main differentiation stages – DC 
precursors, immature DC and mature DC. Immature DC sample the environment for 
the presence of “danger signals”. As soon as iDC detect a danger signal, they undergo 
a complex maturation process. In the process of maturation, DC change their 
expression profile of surface markers resulting in an augmented capacity to activate 
naive and memory T-cell responses. Furthermore, DC may also secrete high levels of 
pro-inflammatory cytokines and can acquire the capacity to migrate towards lymph 
nodes. In order to use DC as an adjuvant for anti-tumor vaccinations, it is necessary to 
understand how DC development and function are regulated. We therefore 
investigated the intracellular signaling pathways that regulate different functions of 
DC. This study focused on the glycogen synthase kinase 3 (GSK-3) pathway. 
GSK-3 is a multifunctional enzyme that is involved in a wide range of cellular 
processes, including cellular differentiation, apoptosis, self renewal and motility. 
More than 40 proteins including 17 transcription factors have been reported to be 
substrates of GSK-3 (reviewed in [226]). GSK-3 is negatively regulated by several 
upstream pathways, including the PI3K/Akt-1 pathway [226]. The PI3K/Akt-1 
pathway was shown to inhibit pro-inflammatory cytokine production (including IL-12 
[141, 238] and TNF-α [239]) of DC and monocytes, and enhance IL-10 production 
[240]. Furthermore, GSK-3 inhibitors were recently demonstrated to enhance IL-10 
secretion and inhibit IL-12p40, IL-6 and TNF-α secretion of human monocytes [214]. 
Moreover, GSK-3 dysregulation is involved in several neurologic diseases such as 
bipolar mood disease [201, 202] and schizophrenia [203] that can be associated with 
an increased serum levels of pro-inflammatory cytokines (such as IL-6 and TNF-α 
and IL-12p70) [209-212]. These pro-inflammatory cytokines can be produced in large 
amounts by activated DC. Based on these observations, GSK-3 is a candidate 
regulator of DC function.  
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Using an in vitro model of DC differentiation from human CD14+ monocytes, we 
investigated the involvement of GSK-3 in regulation of three main differentiation 
stages of DC – DC precursors (monocytes), immature DC and mature DC. 
4.2.1 Specificity of GSK-3 inhibitors 
In the present study, the involvement of GSK-3 was investigated by blocking GSK-3 
activity with 4 different GSK-3 inhibitors: LiCl, SB216763, SB415286 and 
1-azakenpaullone. Selectivity is a key issue when GSK-3 inhibitors are used to 
demonstrate the involvement of GSK-3 in a cellular process. We therefore used the 
inhibitors that inhibit GSK-3 by two different mechanisms. Lithium inhibits GSK-3 
directly by outcompeting Mg2+ [232] and indirectly by activating the Akt-pathway 
[233]. Lithium therefore is not very specific for GSK-3. SB216763, SB415286 and 1-
azakenpaullone compete with ATP in the ATP-binding site of the kinase. These 
inhibitors appear to be among the most specific GSK-3 inhibitors identified so far 
[241]. None of the inhibitors used in this study distinguish between GSK-3α and 
GSK-3β isoforms. 
As the effects reported in this study were confirmed using several GSK-3 inhibitors 
that differ in chemical structure and mechanism of inhibition, they are most likely to 
result from the reduction of GSK-3 activity and not by side effects. 
4.2.2 GSK-3 modulates monocyte differentiation: DC versus macrophages 
Monocytes represent 5-10% of peripheral blood leukocytes. There are two major 
outcomes of monocyte differentiation: they can develop into macrophages or can 
become DC. Functionally, macrophages exhibit high phagocytic activity and rapidly 
degrade engulfed material [242], but fail to prime T-cell response in vivo [243, 244]. 
In contrast, although DC exhibit lower phagocytic activity and lower proteolytic 
activity than macrophages [242], they effectively process and present antigens on 
MHC class I and class II in context of appropriate costimulation [118] for effective 
priming of T-cell response. Moreover, macrophages and DC differ in migratory 
properties. Macrophages are mainly retained in the tissues, whereas DC can acquire 
the capacity to migrate towards lymph nodes in order to interact with T-cells and 
prime immune responses [137]. Therefore, macrophages are thought to be more 
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important for the local clearance of bacteria and dead cells, whereas DC have a major 
role in initiating adaptive T-cell responses. 
It was recently demonstrated that GSK-3 is constitutively active in human CD14+ 
monocytes [214]. Using an in vitro model of differentiation of human monocytes into 
DC in presence of GM-CSF and IL-4, we demonstrated that GSK-3 is crucially 
involved in this process. The present study shows that during the early stages of cell 
culture in GM-CSF and IL-4, GSK-3 inhibitors shift the differentiation of monocytes 
from developing into DC toward the macrophage lineage. The observed effect of 
GSK-3 inhibitors might be explained in several ways. In the presence of GM-CSF and 
IL-4, GSK activity can either promote differentiation of monocytes into DC or inhibit 
differentiation of monocytes into macrophages. IL-4 is known to be crucial for 
differentiation of monocytes into DC. In the presence of GM-CSF and absence of IL-
4, human monocytes differentiate into macrophages [245]. Therefore, the effects of 
GSK-3 inhibitors on differentiation of human monocytes in the presence of GM-CSF 
and IL-4 suggest that GSK-3 might be involved in the IL-4 signaling pathway. 
Signaling pathways activated by IL-4 receptor engagement involve PI3K/Akt and 
Ras/MAPK pathways (reviewed in [246]). Activation of these pathways is mediated 
by Janus kinase family (Jak1 and 3) and insulin receptor substrate (IRS) 1 and 2. Jak1 
and 3 also recruit Stat-6, the transcription factor that is critical for the activation or 
enhanced expression of many IL-4-responsive genes. Activation of gene transcription 
by Stat-6 may require cooperative interactions with additional transcription factors, 
such as C/EBPβ [247, 248] and AP1 [249]. Interestingly, C/EBPβ [250] and AP1 
[251] are substrates of GSK-3. C/EBPβ was shown to be positively regulated by 
phosphorylation at a consensus ERK/GSK3 site [250], whereas AP-1 is negatively 
regulated by GSK-3 activity [251]. This suggests a possible mechanism how 
inhibition of GSK-3 activity can change the transcription profile induced by IL-4 and 
thus change the differentiation program of human monocytes. 
Another issue to be considered is heterogeneity of the human monocyte population. 
Potentially, there can exist two subsets of monocytes, one predisposed to differentiate 
into DC and the other prone to differentiation into macrophages. For example, two 
major subsets of human peripheral blood monocytes differing in CD14 and CD16 
expression were described: the so-called ‘classical’ CD14+CD16- monocytes, 
representing around 90% of monocytes in healthy individual, and the ‘non-classical’ 
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CD14lowCD16+ monocytes comprising the remaining fraction [252, 253]. Several 
studies have analyzed the differentiation of these monocyte subsets in vitro. Some of 
them demonstrated that CD14lowCD16+ monocytes in the presence of vascular 
endothelial cells are more prone to become DC [254]. However, it was demonstrated 
that in presence of human epidermal environment CD14+CD16- monocytes can 
differentiate into Langerhans cells [255]. Therefore, the relevance of CD16 expression 
for monocyte differentiation fate is not yet clarified. Nevertheless, the possibility of 
the presence of two monocyte subsets differing in predisposition to differentiate 
toward DC or macrophage lineage can not be excluded. If this is the case, GSK-3 
activity could differentially influence the survival of these two monocytic 
subpopulations. 
We have not investigated, whether there is a defined subpopulation of monocytes that 
differentiates into DC and whether there are specific subpopulations that die. In our 
model yields of DC comprise 20-40% of the initial monocyte population, whereas 60-
80% of the monocytes are dying within 5-7 days of culturing. Yields of viable cells 
were lower in cultures containing GSK-3 inhibitors (62+/-9% compared to 100% 
without inhibitors). As the yields were comparatively low, we are not able to exclude 
the existence of a few separate populations of monocytes in the cultures. We can 
therefore not tell whether GSK-3 inhibitors changed viability of a certain monocyte 
subpopulation or if the inhibitors changed the developmental program of the same 
population. However, both monocyte-derived cell types after 5 days (DC and 
macrophage-like cells differentiated in the presence of GSK-3 inhibitors), represented 
homogeneous populations by phenotype (Figure 9C) rather than two distinct 
populations. This observation indirectly favours the hypothesis that GSK-3 inhibitors 
change the developmental program of the same monocyte population. In order to 
finally clarify this issue, single cell experiments would be needed. However, single 
cell experiments with non-proliferating DC precursors are not possible at the moment. 
4.2.3 Spontaneous maturation of monocyte-derived DC is inhibited by GSK-3 
As outlined above, GSK-3 is constitutively active in immature MoDC and inhibits 
their spontaneous maturation in culture, as demonstrated by increased CD80, CD83 
and CD86 expression and IL-6 secretion in presence of GSK-3 inhibitors. The 
mechanism by which GSK-3 inhibits spontaneous maturation of monocyte-derived 
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DC is not clear. One possible candidate for maintaining DC in immature state in the 
absence of maturation stimuli is the GSK-3 substrate β-catenin. Active GSK-3 
associates with cytoplasmic β-catenin and reduces its levels by targeting β-catenin for 
proteasomal degradation. There are three functionally distinct pools of β-catenin in 
the cell: 1) in adherent junctions, directly associated with the cytoplasmic part of E-
cadherin; 2) in the cytoplasm 3) in the nucleus, associated with transcription [256]. 
The levels of β-catenin in these three pools are influenced by one another. For 
example, differences in E-cadherin expression affect the cytoplasmic β-catenin pool 
and an increase in cytoplasmic β-catenin levels (e.g. as a result of GSK-3 inhibition) 
induce its nuclear translocation and subsequent initiation of β-catenin target gene 
transcription [257]. Interestingly, E-cadherin was shown inhibit maturation of CD34+-
derived human Langerhans cells [258]. In this study, spontaneous maturation (in 
presence of the cytokines used for differentiation of CD34+ cells into Langerhans 
cells, i.e. TGF-β1, GM-CSF, TNF-α, SCF and Flt3 ligand) was induced by disruption 
of immature cell clusters. This effect was due to disruption of E-cadherin signaling, as 
the addition of an E-cadherin-specific mAB blocked spontaneous maturation of 
Langerhans cells [258]. As E-cadherin associates with β-catenin in adherent junctions, 
it is possible that the spontaneous maturation of monocyte-derived DC caused by 
GSK-3 inhibitors is a result of the changed cellular levels of β-catenin. Further 
experiments are required to verify the role of β-catenin in maturation of MoDC. This 
should be investigated in the future by transfecting DC with β-catenin and β-catenin 
siRNA constructs. 
4.2.4 Stimulus-specific influence of GSK-3 on migration and maturation 
phenotype 
We demonstrate that GSK-3 inhibitors exhibit different effects on phenotypic 
maturation and migration of DC, depending on the activation stimuli. GSK-3 
inhibitors reduce phenotypic maturation of E. coli activated DC (which includes 
CD83 expression), although they do not completely prevent phenotypic maturation 
(Figure 13A). For BHK-CD40L activated DC, GSK-3 inhibitors reduce CD83 
expression only (Figure 13B). Likewise, the migration of E. coli-activated DC was 
inhibited by GSK-3 inhibitors, whereas migration of DC activated with BHK-CD40L 
in presence or absence of a cell permeable cAMP analogue was not significantly 
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altered. This was also reflected by the levels of CC chemokine receptor 7 (CCR7) 
expression. Although SB415286 reduced CCR7 expression in all activation protocols, 
this reduction was most pronounced in E. coli-activated DC where surface CCR7 
expression levels did not differ any more from immature DC (Figure 14C). This may 
explain the differences in DC migration in the presence of SB415286 of BHK-
CD40L-activated DC and E. coli-activated DC shown in Figure 14B. 
The mechanisms underlying these differential effects were not investigated in this 
study. E.coli activation of DC is a result of simultaneous engagement of several TLR 
receptors, whereas CD40L activates DC via CD40 signaling. It is possible that E.coli 
activation induce a strictly GSK-3-dependent phenotypic maturation of DC. GSK-3 
inhibitors therefore decrease expression of all surface maturation markers, including 
CCR7. In contrast, CD40 crosslinking may additionally activate GSK-3-independent 
pathways leading to DC maturation. 
4.2.5 GSK-3 regulates cytokine secretion by activated DC and monocytes 
4.2.5.1 GSK-3 regulates IL-12p70 secretion of activated DC 
Upon activation of DC with intact E.coli or CD40L, IL-12p70 secretion was almost 
completely blocked by GSK-3 inhibitors. GSK-3 is inhibited by the upstream 
PI3K/Akt pathway. This is achieved by Ser21/9 phosphorylation of GSK-3 by Akt-1. 
As was demonstrated previously, IL-12p70 secretion was enhanced in presence of the 
PI3K inhibitor wortmannin ([141] and Figure 15). This coincided with reduced 
phosphorylation of the GSK-3-Ser21/9 moiety. The enhancing effect of wortmannin 
on IL-12p70 secretion could be opposed with the GSK-3 inhibitors SB415286 and 1-
Azakenpaullone, suggesting that the wortmannin effect indeed targeted GSK-3. These 
observations further support the critical role of GSK-3 for IL-12p70 production. 
IL-12p70 is a biologically active form of IL-12. It is a heterodimer, composed of IL-
12p40 and IL-12p35 subunits. Human IL-12p40 expression is primarily regulated at 
the transcriptional level, whereas IL-12p35 expression has been reported to be 
regulated on multiple levels, including both, transcriptional and translational 
mechanisms, as well as post-translational modifications (summarized in [259]). GSK-
3 could therefore influence IL-12-p70 production on several levels, including 
transcription, translation, post-translational modifications and cytokine secretion. 
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In this study, we investigated whether IL-12 p40 and p35 mRNA levels were affected 
by the GSK-3 inhibitor SB415286. We could demonstrate that SB415286 inhibited 
CD40L-induced IL-12p35 mRNA in MoDC. In contrast, IL-12p40 mRNA levels 
responded to GSK-3 inhibitors only after 24 hours following activation. These results 
suggest that GSK-3 regulates IL-12p70 production via specifically regulating IL-
12p35 mRNA levels. 
4.2.5.2 Other pro-inflammatory cytokines 
However, this picture is less clear for the other cytokines investigated. Compared with 
IL-12p70, cytokines such as IL-12p40, IL-6 and TNF-α were only partially inhibited 
by lithium, SB415286 or 1-Azakenpaullone suggesting that GSK-3 dependent and 
independent mechanisms may be involved in their regulation. This is further 
underlined by the lack of efficacy of the GSK-3 inhibitors to block wortmannin-
enhanced IL-6 and TNF-α secretion. Furthermore, RT-PCR quantification 
demonstrated that IL-6 mRNA was differentially influenced in the early and late 
periods following activation, whereas TNF-α mRNA was not significantly influenced 
by GSK-3. IL-12p40 mRNA levels, as mentioned before, responded to GSK-3 
inhibitors only after 24 hours following activation. 
On the other side, wortmannin opposed the effects of SB415286 on IL-6 and TNF-α. 
Although more than one interpretation is possible, this observation may suggest the 
existence of additional inhibitory effects of the PI3K/Akt-1 pathway independent of 
GSK-3. These effects may also involve post-translational processing and regulation of 
secretion of these cytokines. 
4.2.5.3 IL-10  
GSK-3 inhibitors have previously been reported to enhance IL-10 secretion by human 
monocytes [214]. We therefore studied IL-10 secretion by activated human CD14+ 
monocytes and MoDC. We could not detect a significant effect of lithium and 
SB415286 on IL-10 production of CD14+ monocytes activated with intact E.coli. As 
this contradicted the data published by Martin et al., we confirmed our observations 
using positively and negatively selected CD14+ monocytes activated with LPS and 
intact E. coli at high and low concentrations (n=4-16, data not shown). However, the 
differences in IL-10 secretion in the presence or absence of lithium and SB415286 
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were not significant under any of these experimental conditions. Similarly, IL-10 
secretion by MoDC activated with E.coli was not affected by the addition of lithium 
whilst addition of SB415286 only weakly inhibited IL-10 secretion. GSK-3 inhibitors 
as well did not influence IL-10 in CD40L-activated DC. 
The PI3K inhibitor wortmannin inhibited CD40L- and E.coli-induced IL-10 secretion 
in MoDC. These results are consistent with the data that PI3K/Akt pathway enhances 
IL-10 production by human monocytes [240]. Interestingly, SB415286 opposed the 
effect of wortmannin on IL-10 secretion, suggesting that IL-10 production is partially 
inhibited by GSK-3. This was also supported by the observed increased levels of IL-
10 mRNA in the presence of the GSK-3 inhibitor SB415286 in CD40L-activated 
MoDC. This suggests that GSK-3 is a partial regulator of IL-10 production by DC. 
However, additional, GSK-3-independent mechanisms seem to influence IL-10 
secretion by monocytes and DC. 
4.2.6 GSK-3 acquires pro-inflammatory function in activated DC 
This study demonstrates that GSK-3 activity is crucial for IL-12p70 production of 
activated MoDC. Interestingly, GSK-3 is inhibited upon activation, as demonstrated 
by an increase in Ser21/9 phosphorylation levels of GSK-3 upon activation with intact 
E.coli. How can the enzyme that is inhibited upon DC activation enhance IL-12p70 
secretion? Most GSK-3 substrates require “priming”, i.e. phosphorylation by other 
kinases, before they will be further phosphorylated by GSK-3 [260]. A positively 
charged pocket of GSK-3, comprising Arg96, Arg180 and Lys205 residues, optimizes 
binding and orientation of primed targets increasing the efficiency of substrate 
phosphorylation by 100-1000-fold [261]. The inhibitory Ser21/9-phosphorylation 
creates a pseudosubstrate that binds intramolecularly to the positively charged pocket. 
This mechanism of inhibition is competitive so that primed targets, at high enough 
concentrations, out-compete the pseudosubstrate and become phosphorylated [229]. 
Competition between primed targets and the phospho-Ser21/9-moiety of GSK-3 
during DC activation may therefore modulate levels of IL-12p70 production. Kinases 
priming GSK-3 targets may include the MAPK, such as p38K and ERK1/2, as they 
are both activated following DC activation, and a combination of inhibitors of either 
MAPK also blocks IL-12p70 secretion [141]. 
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Our data suggest a scenario where the GSK-3, which has inhibitory function of in 
immature DC, in response to activation stimuli changes into an enzyme with a pro-
inflammatory function (Figure 17). This occurs due to a change of intracellular 
context that is characterized by the emergence of primed GSK-3 targets, i.e. proteins 
phosphorylated by other kinases such as p38K and ERK1/2. Pro-inflammatory 
cytokines such as IL-12p70 are cachectins and have to be tightly regulated. This 
regulation is partially achieved by PI3K/Akt-1 pathway that is activated by all 
maturation inducing stimuli used in our system. Akt-1 phosphorylates the Serine 
residues 21/9 of GSK-3, thereby inhibiting the phosphorylation of the GSK-3-primed 
targets. This results in a down-regulation of IL-12p70 secretion, an effect 
counteracted by wortmannin. However, the phospho-Ser21/9-moiety of GSK-3 acts as 
a competitive inhibitor of the phospho-binding pocket. High concentrations of primed 
GSK-3 targets may therefore successfully compete for access to GSK-3 active center 
resulting in a controlled pro-inflammatory activity of this enzyme. 
Thus, production of IL-12p70 appears to be a result of tight interplay of 1) the activity 
of the kinases priming GSK-3 targets, 2) the activity of Akt-1 which inhibits GSK-3 
and 3) the outcome of competition of primed GSK-3 targets and the phospho-Ser21/9-
moiety for access to the phospho-binding pocket of GSK-3 (Figure 17). 
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Figure 17 GSK-3 integrates activating and inhibitory pathways involved in IL-12p70 
production. GSK-3 is constitutively active in immature DC and inhibits their spontaneous 
maturation. Maturation stimuli induce intracellular kinases that are enhancing (e.g. ERK1/2, 
p38K) or inhibitory (e.g. Akt-1) for IL-12p70 production. Enhanced kinase activity results in 
phosphorylation of proteins, which may thus become primed GSK-3 targets. Akt-1 inhibit 
GSK-3 by phosphorylating the Ser21/9-moiety, which bind the phospho-binding pocket of 
GSK-3 as an intramolecular pseudo-substrate. IL-12p70 production now depends on the 
outcome of competition of primed GSK-3 targets and the phospho-Ser21/9-moiety for access 
to the phospho-binding pocket of GSK-3. 
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Conclusions 
In the first part of the presented work, MHC class I antigens derived from HLA-DP 
alleles and from immunoglobulin A and D constant regions were identified and 
evaluated as potential targets for vaccination of patients with hematological 
malignancies after stem cell transplantation (SCT).  
We identified and characterized 20 peptides derived from polymorphic regions of 
HLA-DP and 12 peptides derived from constant regions of IgA and IgD (6 for each 
isotype). Immunogenicity, crossrecognition (when applicable) and natural 
presentation of selected antigens were tested. 
The IgD-derived immunogenic LLNASRSLEV peptide was demonstrated to induce 
positive CTL responses in 40% of healthy HLA-A2+ donors. This epitope, however, is 
not a suitable target for vaccinations due to the lack of efficient natural presentation 
on the surface of either normal or malignant cells. 
CD8+ CTL responses could be generated against 11 out of 20 HLA-DP-derived 
synthetic peptides. However, CTL clones specific for HLA-DP-derived peptides could 
not be generated and the final characterization of natural presentation of the HLA-DP-
derived peptides was therefore not possible. This failure to generate peptide-specific 
CTL-clones may reflect low frequencies of T-cells recognizing HLA-DP-derived 
peptides in PBMC of normal donors. On the other hand, as CTL responses against 
some peptides were shown, further studies are required to investigate whether CTL 
recognizing these antigens have any impact on GvHD development in patients after 
HLA-DP mismatched allogeneic SCT. Therefore, CTL responses against HLA-DP 
derived peptides should be monitored in the future in patients who developed GvHD 
after allogeneic SCT. 
In the second part of this work the role of GSK-3 pathway in differentiation of DC 
and regulation of DC functions was investigated. 
Our results demonstrate that GSK-3 is a crucial enzyme involved in differentiation of 
DC from monocytes and in the maintenance of an immature phenotype of DC. 
Furthermore, in the context of DC activation, despite partial functional inhibition, 
GSK-3 acquires a novel, pro-inflammatory functional status mediating high levels of 
IL-12, IL-6 and TNF-α secretion, and partially inhibiting IL-10 production. Further 
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studies will have to confirm whether GSK-3 might become a target for therapeutic 
interventions in clinical immune imbalances, such as autoimmune diseases and 
transplantation settings. Modulation of this pathway during the course of vaccine-
based immunotherapy may enhance DC activation in vivo and thus may enhance 
vaccine-mediated immune responses. 
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